Next Article in Journal
The Peroxisome Proliferator-Activated Receptors of Ray-Finned Fish: Unique Structures, Elusive Functions
Next Article in Special Issue
Complex Pathophysiology of Acute Kidney Injury (AKI) in Aging: Epigenetic Regulation, Matrix Remodeling, and the Healing Effects of H2S
Previous Article in Journal
TRPA1 Covalent Ligand JT010 Modifies T Lymphocyte Activation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomolecules
Volume 14
Issue 6
10.3390/biom14060633
biomolecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

How the Western Diet Thwarts the Epigenetic Efforts of Gut Microbes in Ulcerative Colitis and Its Association with Colorectal Cancer

by
Avisek Majumder
* and
Shabana Bano
Department of Medicine, University of California, San Francisco, CA 94158, USA
*
Author to whom correspondence should be addressed.
Biomolecules 2024, 14(6), 633; https://doi.org/10.3390/biom14060633
Submission received: 4 May 2024 / Revised: 24 May 2024 / Accepted: 27 May 2024 / Published: 29 May 2024
(This article belongs to the Special Issue Homocysteine and H2S in Health and Disease)
Browse Figures
Versions Notes

Abstract

:
Ulcerative colitis (UC) is an autoimmune disease in which the immune system attacks the colon, leading to ulcer development, loss of colon function, and bloody diarrhea. The human gut ecosystem consists of almost 2000 different species of bacteria, forming a bioreactor fueled by dietary micronutrients to produce bioreactive compounds, which are absorbed by our body and signal to distant organs. Studies have shown that the Western diet, with fewer short-chain fatty acids (SCFAs), can alter the gut microbiome composition and cause the host’s epigenetic reprogramming. Additionally, overproduction of H2S from the gut microbiome due to changes in diet patterns can further activate pro-inflammatory signaling pathways in UC. This review discusses how the Western diet affects the microbiome’s function and alters the host’s physiological homeostasis and susceptibility to UC. This article also covers the epidemiology, prognosis, pathophysiology, and current treatment strategies for UC, and how they are linked to colorectal cancer.

1. Introduction

Over the years, the dietary habits of Western countries have changed significantly, with an increased consumption of semi-processed and ultra-processed foods [1]. These processed foods contain fewer plant-derived dietary fibers and more easily digestible carbohydrates, fat, emulsifiers (used for food processing), and other additives [1]. These changes in dietary patterns can impact microbial communities and often lead to a condition called dysbiosis [2]. The microbial community in the gut partially ferments and breaks down dietary fibers, producing short-chain fatty acids (SCFAs) and other metabolites [3]. These metabolites can influence various metabolic processes in the host. Studies have shown that microbial metabolic compounds can induce epigenetic reprogramming in the host’s genome [4]. This occurs by changing the pool of substrates used for methylation and acetylation reactions and by generating other compounds that affect the activity of enzymes involved in epigenetic modification [4]. These epigenetic modifications can persist through cell divisions and can be passed down without changes in the gene sequence [5].
Ulcerative colitis (UC), mainly associated with chronic inflammation and ulceration of the colon, is a significant risk factor for the development of colorectal cancer [6]. Different studies have found that UC patients who consume a high-fiber, low-fat diet show reduced inflammation and microbial dysbiosis [7,8]. Although the intestinal microbiota is sensitive to different environmental cues (including diet, stress, medications, etc.) and is associated with chronic diseases like UC, and colorectal cancer, so far, no study has been performed to consider all of these factors together to understand the underlying cause of this disease. Hence in this review article, we describe how the Western diet affects the gut microbial community, leading to epigenetic modification of the host genome. Moreover, we discuss how different microbial metabolites produced from the gut can induce pro-inflammatory signaling during UC. Additionally, we discuss the mechanism of development of UC and how it is linked to colorectal cancer.

2. Outline of Ulcerative Colitis

2.1. Overview

UC is an idiopathic and chronic disease that is also a subtype of inflammatory bowel disease (IBD) [9]. This disease was first described by Samuel Colitis in 1959 [10]. It is an unremitting inflammation of the colon’s mucosal lining [11]. Inflammation in UC starts in the rectum and extends to the proximal segments of the colon [11]. UC leads to small ulcers on the lining of the colon, which can lead to bleeding, diarrhea, pus, cramping/abdominal pain, nausea, and extreme fatigue [11]. Earlier, the exact etiology of UC was not known, but now it is well established that it arises due to dysbiosis of the microbiota and the external environment may play a vital role [11]. The gut microbiome maintains our gut health by regulating the epithelial barrier [12]. It plays a direct role in influencing immune function by provoking a pro-inflammatory environment [12]. SCFAs serve as energy substrates for specific groups of bacteria in our colon and regulate homeostasis in the microbiome [13]. Previous studies suggested that the presence of fewer SCFAs in the Western-type diet can affect the microbiome’s composition [13]. Other than diet, factors like excessive use of drugs, alcohol, smoking, and mental stress can cause dysbiosis by killing beneficial bacteria [14]. As a result, the immune system is activated and targets its own tissue, increasing intestinal permeability and resulting in bloody diarrhea [15,16].
UC is associated with significant morbidity in Western countries, and its incidence is increasing in developing countries [17]. This disease can develop in any individual group, but it is primarily diagnosed in the age group of 30–40 years [18]. This disease has two phases: one phase is called remission, in which diseased symptoms are under control, and the second phase is called the relapse phase, where disease symptoms are expressed, but this phase remains unpredictable [19]. Moreover, this disease is also associated with other manifestations affecting other body organs, like the eye, liver, skin, and joints [15]. Based on the location of the inflammation, UC is divided into five types: proctitis, proctosigmoiditis, distal ulcerative colitis, extensive colitis, and pancolitis (as shown in Figure 1) [20].

2.2. Epidemiology

The epidemiology of UC varies significantly worldwide. A report submitted by Molodecky et al., 2012 says that, from 1930 to 2010, the prevalence and incidence of UC increased worldwide [21]. The maximum incidences of UC have been reported in northern Europe (24.3 per 105), followed by Canada (19.2 per 105) and Australia (17.4 per 105) [21,22,23]. The highest prevalence rates are recorded in Europe (505 per 105), Canada (248 per 105), and the USA (214 per 105) [21,24,25,26]. Although recognition of UC is rising in Asia, the Middle East, and South America, very little data are available from these countries [27,28,29,30]. A study published by Sood et al., 2009 claimed that the prevalence rate of UC was 44.3 per 105 inhabitants and the incidence rate was 6.02 cases per 105 inhabitants in Punjab, North India, when the study was conducted [31]. So far, no sex predominance is reported in the occurrence of UC [32].

2.3. Prognosis

Recent data suggest that less than 10% of UC patients need colectomy within the first ten years of diagnosis [33]. Different factors like disease progression, certain levels of inflammatory markers, and age less than 50 years at diagnosis are associated with colectomy [33]. Modifiable risk factors associated with relapse of the disease are uncertain but could be induced by changes in diet patterns, mental stress, smoking, and poor adherence to drugs [34]. Although the disease may be associated with a modest increase in mortality in the community, this effect is attenuating in more contemporary cohorts of patients, perhaps due to earlier diagnosis and treatment improvement [35].

2.4. Risk Factors

The cause of ulcerative colitis is complex and involves many risk factors. Different clinical studies have found that age, race, ethnicity, genetics, and the gut microbiome are the main risk factors for UC [36]. However, other factors, such as lifestyle, diet, stress, overuse of certain drugs, exercise, and air pollution, can act as triggers for UC [37]. The risk of being diagnosed with UC is higher for individuals aged between 15 and 30, as well as for those older than 60 [38]. This suggests that age is one of the risk factors for UC. Some studies also proposed that people of white ethnicity, particularly those of Ashkenazi Jewish descent, are at greater risk of developing UC [39]. Additionally, having a first-degree relative with UC or Crohn’s disease increases the likelihood of developing UC, as up to 20% of people with UC have a family member who also has UC or Crohn’s disease [39]. These findings provide evidence that suggests that genetics play a vital role in the causation of UC.
Emerging data from cohort studies in the United States and Europe have demonstrated an association between various environmental factors and the risk of UC [40]. Early-life events such as mode of birth (cesarean versus vaginal delivery), breastfeeding, and exposure to antibiotics, as well as factors such as air pollution, smoking, psychological state, exercise, and diet, are among the potential environmental contributors to IBD development or disease activity [41].
Studies found that antibiotics alter the gut microbiome composition, resulting in transiently decreased bacterial diversity, and cessation of antibiotics can return the microbiome to its pre-antibiotic state within ∼1 month [42]. Some studies have also shown associations between antibiotic use and IBD development but were limited due to recall bias [43].
Smoking plays a protective role against UC [44]. Smoking cessation dramatically changes the composition of and increases the variety of the intestinal microbiome [45,46,47]. Environmental pollutants like heavy metals could contribute to inflammatory diseases like IBD. Ingested mercury causes various disturbances in the intestinal tract, such as abdominal pain, IBD, ulcers, and bloody diarrhea [48]. Several studies have proved the association between significant life stressors, anxiety, depression, or psychiatric morbidity and the onset of IBD risk [49,50,51,52].

2.5. Current Treatment Strategies

2.5.1. Immunosuppressants, Steroids, and Biologics

Aminosalicylates are considered a treatment choice for mild to moderate UC, and topical and systemic steroids can be used to treat UC flares [53]. By contrast, immunosuppressants and biological drugs are used in moderate to severe disease [54]. In May 2014, the Food and Drug Administration approved vedolizumab, the first selective adhesion molecule inhibitor for use in moderate to severe UC when standard therapy has failed [55]. Vedolizumab is a humanized monoclonal antibody that inhibits the adhesion molecule a4b7-heterodimer, blocks leukocyte migration and the resultant gut inflammation, and is effective in inducing and maintaining remission in moderate to severe UC [11,56].

2.5.2. Probiotics

Many probiotics have been used to treat various metabolic diseases [57,58,59,60]. Vsl-3 is one of these probiotics that has been evaluated in several studies [61]. It is efficacious in inducing remission in mild to moderate disease. However, data on its use as a maintenance therapy are poor [62,63], and data on the use of other probiotics are quite limited [31,64].

2.5.3. Surgery

Surgery is introduced when therapeutic approaches fail (or corticosteroid dependence is indicated) or in the case of colonic dysplasia or cancer [65]. Approximately 10% to 15% of patients require surgical management of their disease [66,67].

2.5.4. Fecal Microbiota Transplantation (FMT)

Fecal microbiota transplantation (FMT) is the most recent attention-grabbing treatment for UC [68]. This process involves restoring the microbiota by introducing a healthy mass of bacteria through the infusion of stool, e.g., via enema, orogastric tube, colonoscopy, or by mouth in the form of a capsule containing freeze-dried material obtained from a healthy donor [69]. Various studies have shown that FMT is a promising treatment with a high success rate [68].

3. Relationship between Environmental Inputs, Microorganism-Derived Metabolites, and Host Signaling Pathways in UC

Microorganisms closely associate with eukaryotic organisms across the plant and animal kingdoms. Responding to environmental fluctuations, microorganisms quickly alter their transcriptomes, contributing to the host’s physiological homeostasis and disease susceptibility. Microbes and their hosts share the same environment, and microbial metabolic molecules (microbial metabolites) exert crucial effects on host physiology [70]. Environmental factors shape the composition of the host’s resident microbes and modulate their metabolism. In the following paragraphs, we discuss these relationships in detail.

3.1. Gut Microbiome and UC

3.1.1. Composition of the Gut Microbiome

The number of bacterial cells found in the human gastrointestinal (GI) tract (GIT) is ten times the number of human cells and encodes 100 times more genes than the host’s genome [71]. This collection of all microbes, such as bacteria, fungi, viruses, and their genes, naturally living inside our body is known as a microbiome [72]. The colonization of the microbiota does not occur in the uterus, and the fetus, believed to be sterile or least microorganism-containing, develops microflora during the passage of the fetus through the vagina [71]. This is why the child’s gut shows a similar microbiota to the mother’s vaginal area when born by vaginal delivery. By contrast, babies born by cesarean section initially show fewer bacteria in comparison to infants who are delivered through the vaginal pathway [73]. However, these differences are not seen after 6 months of birth [73]. The bacteriology of the human GIT is extensive and beyond the scope of this review; we focus on how microbial metabolites can reprogram the host’s epigenetic code and how that relates to UC. In earlier times, studying the colon’s microbiota was extremely meticulous because culture-based methodology was used, and the culture of anaerobes was the hardest part. However, robust changes have occurred in microbiology techniques in the last decade by introducing culture-independent, high-throughput molecular techniques like 16S rRNA sequencing [74]. Data obtained from different studies show that around 2000 species can co-exist in the human GIT [75]. These microbes can be grouped into 12 phyla, of which approximately 94% belong to Actinobacteria, Bacteroidetes, Firmicutes, and Proteobacteria [75]. It was also noted that more than 380 identified species are anaerobic [76]. A study reported that a healthy person’s colon has about 500 different bacterial species belonging to 190 different genera [77]. Long-term colonization of microorganisms is suggested to be essential for normalizing the host’s colon mucous layer [78]. Although the mucous layer is present in the entire GIT, it is thickest in the colon, and this area plays a significant role in the relationship between the host and microbes [78]. The colonic mucous layer is divided into two different layers; the inner layer is impermeable and dense and is believed to be virtually sterile, while the outer layer is loosely structured and penetrable by microorganisms [75,79]. The outer layer contains mucin protein, which is decorated by the receptors of O-glycans, which provide binding sites and energy to commensal bacteria [80,81,82] (Table 1).

3.1.2. Role of the Gut Microbiome in the Causation of UC

A plethora of evidence has confirmed that dysbiosis of the GI microbiota leads to various diseases like IBD and other gastrointestinal disorders [83,84]. UC is a subtype of IBD, which also develops due to microbiota dysbiosis. Dysbiosis of the microbiota is a phenomenon where the alteration of the ecosystem of the microbiota takes place with respect to pathogenesis. A study by Machiels and colleagues (2014) compared the microbiota of UC patients (127 patients) over 85 years of age with sex-matched healthy people [85]. They found that the numbers of two bacterial strains, namely Raecalibacterium prausnitzii and Roseburia hominis, were significantly lower in UC compared to the control, and recently, another group confirmed this finding [85,86]. In another study, it was seen that alteration in the combination of the microbiota and disturbance in fermentation in IBS patients may play a crucial role in the development of symptoms of IBD patients, with a significant two-fold increase in the ratio of Firmicutes to Bacteroidetes reported in IBS patients [87]. In other studies, in UC patients, it was found that there was a decrease in bacterial diversity, a noticeable fall in the number of Firmicutes, and an increase in the number of Gammaproteobacteria and Enterobacteriaceae [88]. It has been seen in various studies that the gut microbiota maintains epithelial integrity and tight junction permeability. For example, Lactobacillus plantarum was reported to maintain the integrity of tight junction proteins against disruption of the epithelial barrier [89]. The loss of epithelial integrity permits gut bacteria, toxins, partially digested food, and waste material to pass through the epithelium into the bloodstream, which triggers the immune responses leading to gastrointestinal problems, such as cramps, excessive gas, abdominal bloating, and food sensitivities. These are the symptoms of a leaky gut, which displays hyperpermeability, resulting in bloody diarrhea [90].

3.2. Western Diet, the Microbiome, and UC

3.2.1. Western Diet and Its Impact on Health and Disease

Before the agricultural revolution and animal farming, hominins’ main diet was limited to minimally processed wild plant and animal foods [91]. After the Industrial Revolution, different ultra-processed and refined foods were introduced that were not previously encountered in hominin evolution [91]. Hence, it is not hard to believe that adaptation to changes in diet may contribute to various chronic diseases [91]. In the US, approximately 65% of adults (aged 20 and above) are either overweight or obese, and obesity alone is attributed to a total of 280,184 deaths per year [92]. In an estimation, it was noted that about one-third of all cancer deaths are due to poor dietary habits and obesity [91]. These statistics undeniably illustrate the detrimental impact of the Western diet that diverges from our ancestors’ nutritional model.
The Western diet is typically defined by the consumption of energy-dense but nutrient-poor processed and refined foods (like fast food and soft drinks), which are often high in added sugars, salt, and saturated fats [93]. By contrast, traditional non-Western diets, particularly the Mediterranean diet, contain whole grains, healthy fats, legumes, and a greater portion of vegetables and fruits [94]. Western foods are those foods that are altered from their natural condition to improve test, self-life, and energy value [93]. These foods also include processed meats (mostly red meats), which have been associated with risk for many metabolic diseases and colorectal cancer [95]. Furthermore, processed and refined foods comprise a significant portion of the typical Western diet, which mainly include cookies, cake, bakery goods, breakfast cereals, and snack bars [96]. It is important to note that dairy products, cereals, refined sugars, refined vegetable oils, and alcohol collectively account for 72.1% of the total daily energy consumed in the United States [97].
The Western diet and its adulteration with substances directly impact gut microbes and, consequently, human health [97]. During the agricultural process, some additives are used to increase productivity by enhancing resistance to pests and increasing crop yields [98]. In addition, during food processing, different additives (including preservatives, flavor, and sugar alternatives) are added knowingly or accidentally [99]. Common non-nutritive substances found in Western foods include pesticides, persistent organic pollutants (POPs), metals, and plasticizers [100]. These chemicals have been linked to different detrimental effects on our bodies.
Animal-source foods are packed with vital vitamins and minerals crucial for good health [101]. Deficiencies in these nutrients can lead to serious health issues [102,103]. That is why the traditional rural American farm diet, mainly eggs, meat, and milk, has been associated with improved health and increased longevity.

3.2.2. Western Diet Affects the Microbiome Composition in Relation to UC

Many factors shape the microbiota composition of the GI, but diet is one of the most important factors in maintaining the diversity of the microbiota of the GI [104]. It has also been noted that considerable changes in feeding habits increase the chances of UC [105]. Many epidemiological studies have proved this relationship between food and UC [90]. Two recent studies have shown that sucrose intake and soft drink consumption are related to the development of UC, and the risk of disease development was 10% and 69%, respectively [106,107]. Another study showed that consuming fruits and vegetables decreases the chance of UC development [106]. For example, children from rural areas of Africa show low counts of Firmicutes and Enterobacteriaceae and high counts of Bacteroidetes compared to children from European countries [108]. This variation is supposed to be due to the different dietary patterns of both populations [109]. Hence, it has been suggested that feeding habits can induce changes in the microbiota from a healthy state to a diseased state, which can further induce inflammatory diseases like UC [104]. A study also showed that an increase in pro-inflammatory bacteria and a decrease in protective bacteria could result from mucosal dysbiosis of the GIT, which is developed by consuming a high-fat/sugar diet [110].
Furthermore, diet pattern not only affects the microbial composition but also affects the metabolic function of microbes in the GI (Figure 2). Fatty acids with less than six carbons are called short-chain fatty acids (SCFAs), like formic acid, acetic acid, propionic acid, butyric acid, and valeric acid. SCFAs are derived from commensal bacteria when dietary fibers are partially digested [111]. More than 95% of SCFAs in the gut have less than four carbons, namely acetate, propionate, and butyrate [112]. These SCFAs play an essential role in immune modeling and maintain intestinal barrier integrity by controlling the mucosal barrier function of the GI [113]. Several cellular functions, like alteration of gene expression, cellular differentiation, apoptosis, and chemotaxis, and other functions of epithelial and/or immune cells are tightly regulated by SCFAs [114]. In some UC patients, it was found that levels of an essential SCFA-producing bacterium, Faecalibacterium prausnitzii, were decreased, and its activity was inversely proportional to the severity of the disease [85]. Moreover, in Western countries, people eat more sugar and less fiber, which decreases the survival of SCFA-producing bacteria and increases the chances of development of UC [110,115].

3.2.3. Western Diet Thwarts Epigenetic Efforts of the Gut Microbiome in Relation to UC

The gut microbiota produces a variety of metabolites that can be detected in the host’s circulation, including small organic acids, bile acids, vitamins, choline metabolites, and lipids [116]. When the mammalian host cannot digest certain dietary poly- and oligosaccharides, they pass to the distal gut, where they become carbon and energy sources for gut bacteria [116]. Through fermentative reactions, the gut microbiota can metabolize complex carbohydrates to produce small organic acids, mainly comprising SCFAs like acetate, propionate, and butyrate (≥95%), as shown in Figure 3 [3]. Different preclinical studies have shown that microbes communicate with their host by sending out metabolites that act on DNA methylation, post-translational modification of histones, and regulation of non-coding RNAs, thus influencing gene expression in the colon and tissues in other parts of the body [117]. In the following paragraphs, we discuss these epigenetic modifications through the microbiota in detail.

Regulation of DNA Methylation via the Gut Microbiome

DNA methylation is a process of adding methyl groups (-CH3) onto the cytosine residues in DNA, thus affecting gene expression. In DNA methylation, the methyl group comes from the methionine cycle [118,119]. During the methionine cycle, first the amino acid methionine (which comes from diet) is converted to S-adenosyl methionine (SAM), then different DNA methyltransferases (DNMTs) transfer the methyl group from SAM to cytosine residues of DNA, producing S-adenosyl homocysteine (SAH) [120,121]. In addition to methionine (an essential amino acid), metabolites such as folate, vitamin B12, betaine, and choline are essential for SAM production [122,123,124]. Different studies have found that microbial metabolism absorbs these metabolites [125,126]. A study reported that SCFAs (derived from the microbiota, as mentioned above) can regulate the phosphorylation of ERK and cause downregulation of DNMT1 and, consequently, demethylation of tumor suppressor genes, including RARB2, p21, and p16 [127].

Regulation of Post-Translational Modification of Histones via the Gut Microbiome

The eukaryotic genome is organized into a highly compressed nucleo-protein structure known as chromatin, where DNA wraps around histone proteins and folds to form higher-order structures [128]. Different types of post-translational modifications of histones are acetylation, methylation, phosphorylation, SUMOylation, poly-ADP ribosylation, biotinylation, ubiquitination, citrullination, and proline isomerization, and these modifications can influence gene expression [129,130]. Acetylation occurs in the Lys residue of histone tails. It minimizes the positive charge of histone, reducing the interaction between histone and DNA; as a consequence, it opens the regulatory regions of genes so different TFs can bind and promote transcription. Whereas methylation either activates or represses transcription [131]. Histone acetyltransferases (HATs) transfer the acetyl group from acetyl-coenzyme A (acetyl-CoA) to the lysine residue of histone protein, whereas histone deacetylases (HDACs) reverse this reaction [118]. Increased availability of acetyl-CoA can upregulate HAT activity, and studies have found that gut microbiota-derived metabolites SCFAs can modulate acetate (acetyl-CoA) levels [132]. Microbiota-derived SCFAs were also found to inhibit HDAC activity in the host tissue [132]. A study showed that HF/HS feeding of mice reduced SCFA production from the gut microbiota, leading to decreased global histone acetylation in the liver and adipose tissue of the mice [117]. This study also found that HF/HS feeding altered the methylation signature of histone in the mice. Many other studies have reported modulation of the post-translational modification of histones in colonic cells via microbiota-derived SCFAs, which led to differences in IBS [133].

Regulation of Non-Coding RNA via Gut Microbiome

Recently, different non-coding RNAs (RNAs that are not translated into proteins), such as microRNA (miRNA), short-interfering RNAs (siRNAs), piwi-interacting RNAs (piRNAs), and long noncoding-RNAs (lncRNAs), have been identified to be associated with various diseases [134,135,136]. A study identified the alteration of six lncRNAs in the intestinal epithelial tissues of mice when they compared germ-free mice with conventional mice (re-colonized with mice microbiota) [137]. In another report, when researchers compared the microbiota-mediated changes of lncRNAs in different tissues, such as in the liver, duodenum, jejunum, ileum, white adipose tissue, brown adipose tissue, colon, and skeletal muscle, they found significant alteration of lncRNAs only in the jejunum [138]. In an investigation, Virtue et al. identified the upregulation of miR-181a and miR-181b in epididymal white adipose tissues of conventional mice compared to germ-free mice [139].

3.2.4. Western Diet Causes Colonic Inflammation through the H2S-Producing Gut Microbiome in Relation to UC

Excessive consumption of sugar and red meat (Western diet pattern) is known to increase the risk for UC, and a high-fiber diet and citrus fruits have been found to play a protective role in UC [140]. However, this association between the Western diet and UC is far more complex than we think. Other than distinct clinical features, inflammation of intestinal mucosa is the main characteristic of UC [140]. Studies have shown that excessive production of H2S from the microbiota in the context of reduced capacity of sulfide disposal in the mucosa may contribute to inflammation in UC [141]. The severity of the inflammation in the colon and rectum of UC patients is associated with a higher ratio of H2S-producing bacteria than other bacteria in the gut [142]. As the ratio of H2S-producing bacteria depends on the food available for producing these metabolites, the Western diet pattern may contribute to colonic inflammation by increasing the ratio of H2S-producing bacteria in the gut. A follow-up study of UC patients for one year showed that the relapse rate was higher in patients with high consumption of meat, dietary protein, and sulfur/sulfate than in patients with low consumption of these compounds [143]. This suggests that the intestinal bacteria may use these foods for H2S synthesis, which may associated with increased relapse in UC patients. Another study in a rat model showed that intracolonic instillation of NaHS (for 1 H at concentrations of 0.5–1.5 mM) increased the expression of inflammation-related genes like inducible nitric oxide synthase (iNOS) and interleukin-6 (IL-6) [144]. In a study, when the microbiota composition was analyzed in newly new-onset pediatric Crohn’s disease patients, they found enrichment of H2S-producing bacteria like Atopobium, Fusobacterium, Veillonella, Prevotella, Streptococcus, and Leptotrichia [145]. These genera of bacteria are known to produce H2S from sulfur-containing amino acids, and it has been proposed that excessive intake of sulfur (mainly from red meat) in the diet can lead to intestinal problems, including UC [146]. To investigate the direct association of H2S production via the gut microbiota and colonic inflammation, in an experiment, researchers colonized the H2S-producing bacterium Atopobium parvulum into the gut of IL-10 double knockout mice (a model of mice susceptible to colitis). They found worsening of colitis, whereas this effect was attenuated via treatment with an H2S scavenger, bismuth [145]. Additionally, the colonic mucosa biopsy results of the above-mentioned Crohn’s disease pediatric cohort showed lower expression of mitochondrial enzymes, which are involved in H2S detoxification [145].
From the above preclinical and clinical data, it is evident that excessive production of H2S by gut microbiota (i.e., above the capacity of the intestinal mucosa to detoxify it) may cause colonic inflammation in UC, as shown in Figure 4. However, many recent studies have proposed that H2S is a beneficial gasotransmitter (it does not require a transporter protein) that can come from the intestinal microbiota and is produced endogenously via the trans-sulphuration pathway [147,148,149]. Different studies, either using H2S-releasing compounds or inhibiting H2S-producing enzymes, have proposed that minimal H2S is necessary to limit colonic mucosal inflammation risk [150,151,152]. H2S has been shown to have antioxidant capacity via scavenging of ROS and persulfidation of cysteine residues, and this activity of H2S may primarily contribute to its anti-inflammatory properties [153,154,155,156]. Endogenous synthesis of H2S was found to protect against dextran sodium sulfate (DSS)-induced colitis via inhibition of the inflammasome pathway [157]. Similarly, slow-releasing sulfide donor compound GYY4137 was reported to ameliorate lipopolysaccharide- or TNF-α/IFN-γ-induced increased permeability in the colonocyte monolayer [158]. Moreover, the releasing compound was found to improve mesenteric perfusion and intestinal injury in an experimental model of necrotizing enterocolitis via an eNOS-dependent signaling pathway [159].

4. Association of the Microbiome with the Modulation of Immunological Signaling in UC

Both innate and adaptive immunity generate abnormal inflammation in UC patients [160]. The human GI tract has a mucous layer as the first physical barrier of innate immunity, which is composed of two layers, the inner and outer layers (Figure 5) [161,162]. The inner layer is considered sterile, while various commensal bacteria inhabit the outer layer. Next, the intestinal epithelium is considered the second barrier that checks the entry of bacteria, and it comprises enterocytes and specialized cells known as goblet and paneth cells [163]. Intestinal epithelial cells (IECs) protect the mucous barrier by blocking the influx of commensal bacteria and pathogens and secreting mucin and α defensin [164]. It also expresses antigen-sensitive receptors like toll-like receptors (TLRs) and nucleotide oligomerization domain receptors (NOD). Under healthy conditions, the intestinal epithelium is intact, but in UC, an impaired intestinal epithelium allows the entry of pathogens, and TLRs recognize the pathogens and activate the signaling of pro-inflammatory cytokines like interleukin (IL), IL-12, and IL-6 by IECs [165]. TLR signaling also regulates the activation of transcription factor NF-kB, which regulates the various genes responsible for innate responses like IL-1, -2, -6, and -12, and tumor necrosis factor-alpha (TNF-α) [166,167]. IL-1 and TNF-α are well known for their pro-inflammatory responses [168]. TNF-α plays a crucial role in the development of UC because it increases the expression of IL-1β, IL-6, and IL-33 [169,170]. It was also seen that the severity of UC was correlated with the level of TNF-α in the serum of the patients [171]. Besides the above-mentioned interleukins, other interleukins like 1L-8, IL-10, and IL-33 are also involved in UC pathogenesis [172]. A report showed that the IL-10 level in mucosal T cells was increased in UC patients compared to the control group [173]. On the other hand, it was the same in the serum of both UC patients and the control group [174]. Different interleukins control the migration of immune cells at the site of inflammation. For example, IL-8 acts as a chemoattractant, which induces the migration of neutrophils from peripheral blood to inflamed tissue [175]. Various studies have shown that IL-6 and its soluble receptors are increased in UC patients and play an essential role in the pathogenesis of UC and colorectal cancers related to UC [176]. T cells, part of adaptive immunity, also participate in UC [177]. T cells differentiate into Th17 cells when they encounter inflammatory mediators in the GI. Naive T cells also differentiate into regulatory T cells, Th1, Th2, and Th17, through a controlled process [178]. In a healthy state, the intestinal mucosa controls inflammation by Th1, Th17, Th2, Th3, Th9, and T reg cells. The breakage of self-antigen tolerance in the intestinal mucosa, by injury or genetic predisposition, may lead to UC [179]. In UC, there is a substantial increase in the secretion of IL-13, the main interleukin responsible for the inflammation and chronicity of this condition [180]. Despite Th1 involvement, UC patients also present a Th2 response, with increased secretion of IL-4, IL-5, and IL-9 [181,182]. The secretion of specific cytokines such as TNF-α [183,184,185], transforming growth factor-beta (TGF-β) [186,187], and interferon-gamma (IFN-γ) [188,189], as well as the response to self-antigens, are responsible for the development of UC [190,191].
Different clinical [192] and preclinical [193,194] studies recently identified that ECM degradation precedes inflammation in UC. These studies suggest that dysregulated ECM production and degradation leads to inflammation and pathogenesis in UC. A large body of evidence supports that the intestinal tissue of IBD patients overexpresses ECM remodeling enzymes, including matrix metalloproteases, heparanases, and elastases [195,196,197,198]. Secretion of these enzymes increases epithelial permeability and proinflammatory signaling loops and promotes colitis-associated tumorigenesis in mice [199,200].

5. Risk of Colorectal Cancer in UC

It is now well established that not only genetic factors but also various environmental factors can induce the risk of cancer [201,202,203]. In 1925, Crohn and Rosenberg proposed a link between inflammatory bowel disease (IBD) and colorectal cancer (CRC) for the first time, and studies have since confirmed this association [204]. Although IBD accounts for only 1%-2% of all CRC cases, 10%-15% of deaths in IBD cases are due to CRC [205]. While it is widely recognized that the risk of CRC is significantly higher in the UC cohort compared to the general population, the incidence rate may vary based on geographical location and ethnicity [206,207,208,209,210]. A meta-analysis of 116 articles found 1698 CRC cases out of 54,478 UC patients [206]. This study also reported that the incidence rate was higher in the US and UK than in Scandinavia.
A study showed ten new CRC cases after a follow-up of 689 UC patients in Florence between 1978 and 1992 [211]. Similarly, another study reported 36 colon and 13 rectal cancers after following up with 2672 patients [212]. In comparison, a report noted only 13 CRC cases among 1160 patients with UC in Denmark [213]. As it is difficult to follow up with UC patients to account for the development of CRC, many studies have reported a distribution of incidence rates, which we summarized in Table 2.
The inflammation caused by UC is the primary factor that leads to the progression of the disease and is therefore considered a risk factor for the development of CRC [216]. While most cases of sporadic CRC arise from a preceding adenoma and are associated with unique genetic changes, an increased risk of CRC is believed to be an acquired event in inflammatory bowel disease (IBD) [217]. Studies suggest that various environmental factors, including diet and the microbiota, contribute to this risk [217]. Additionally, several studies have suggested various ways to reduce the risk of CRC development in UC patients. In clinical practice, colonoscopy surveillance is routinely recommended for early detection of CRC in UC patients, which can help in subsequent treatment [218]. However, it should be noted that colonoscopic surveillance does not reduce the risk of CRC.

6. Conclusions

A critical analysis of the available literature on UC shows that various factors play essential roles in UC development, but the factors connected with the health and growth of the gut microflora are most important, as shown in Figure 6. Studies have shown that the microflora is essential for the physical and physiological health of the gut, as well as the factors that kill beneficial bacteria and give harmful bacteria the chance to grow, resulting in the activation of immune cells. This consequently leads to UC and other complicated diseases, like colorectal cancer.

Author Contributions

Conceptualization, A.M. and S.B.; writing—original draft preparation, A.M. and S.B.; writing—review and editing, A.M.; All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Clemente-Suárez, V.J.; Beltrán-Velasco, A.I.; Redondo-Flórez, L.; Martín-Rodríguez, A.; Tornero-Aguilera, J.F. Global Impacts of Western Diet and Its Effects on Metabolism and Health: A Narrative Review. Nutrients 2023, 15, 2749. [Google Scholar] [CrossRef] [PubMed]
  2. Yan, J.; Wang, L.; Gu, Y.; Hou, H.; Liu, T.; Ding, Y.; Cao, H. Dietary Patterns and Gut Microbiota Changes in Inflammatory Bowel Disease: Current Insights and Future Challenges. Nutrients 2022, 14, 4003. [Google Scholar] [CrossRef] [PubMed]
  3. Den Besten, G.; van Eunen, K.; Groen, A.K.; Venema, K.; Reijngoud, D.J.; Bakker, B.M. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid Res. 2013, 54, 2325–2340. [Google Scholar] [CrossRef] [PubMed]
  4. Woo, V.; Alenghat, T. Epigenetic regulation by gut microbiota. Gut Microbes 2022, 14, 2022407. [Google Scholar] [CrossRef] [PubMed]
  5. John, R.M.; Rougeulle, C. Developmental Epigenetics: Phenotype and the Flexible Epigenome. Front. Cell Dev. Biol. 2018, 6, 130. [Google Scholar] [CrossRef]
  6. Lakatos, P.L.; Lakatos, L. Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies. World J. Gastroenterol. 2008, 14, 3937–3947. [Google Scholar] [CrossRef] [PubMed]
  7. Fritsch, J.; Garces, L.; Quintero, M.A.; Pignac-Kobinger, J.; Santander, A.M.; Fernández, I.; Ban, Y.J.; Kwon, D.; Phillips, M.C.; Knight, K.; et al. Low-Fat, High-Fiber Diet Reduces Markers of Inflammation and Dysbiosis and Improves Quality of Life in Patients With Ulcerative Colitis. Clin. Gastroenterol. Hepatol. 2021, 19, 1189–1199.e1130. [Google Scholar] [CrossRef] [PubMed]
  8. Nieva, C.; Pryor, J.; Williams, G.M.; Hoedt, E.C.; Burns, G.L.; Eslick, G.D.; Talley, N.J.; Duncanson, K.; Keely, S. The Impact of Dietary Interventions on the Microbiota in Inflammatory Bowel Disease: A Systematic Review. J. Crohns Colitis 2023, jjad204. [Google Scholar] [CrossRef] [PubMed]
  9. Dahlhamer, J.M.; Zammitti, E.P.; Ward, B.W.; Wheaton, A.G.; Croft, J.B. Prevalence of Inflammatory Bowel Disease Among Adults Aged ≥ 18 Years—United States, 2015. MMWR Morb. Mortal. Wkly. Rep. 2016, 65, 1166–1169. [Google Scholar] [CrossRef]
  10. Wilks, S. Morbid appearances in the intestine of Miss Bankes. Med. Times Gaz. 1859, 2, 264–265. [Google Scholar]
  11. Ungaro, R.; Mehandru, S.; Allen, P.B.; Peyrin-Biroulet, L.; Colombel, J.F. Ulcerative colitis. Lancet 2017, 389, 1756–1770. [Google Scholar] [CrossRef] [PubMed]
  12. Sanders, D.J.; Inniss, S.; Sebepos-Rogers, G.; Rahman, F.Z.; Smith, A.M. The role of the microbiome in gastrointestinal inflammation. Biosci. Rep. 2021, 41, BSR20203850. [Google Scholar] [CrossRef] [PubMed]
  13. Portincasa, P.; Bonfrate, L.; Vacca, M.; De Angelis, M.; Farella, I.; Lanza, E.; Khalil, M.; Wang, D.Q.; Sperandio, M.; Di Ciaula, A. Gut Microbiota and Short Chain Fatty Acids: Implications in Glucose Homeostasis. Int. J. Mol. Sci. 2022, 23, 1105. [Google Scholar] [CrossRef] [PubMed]
  14. Martinez, J.E.; Kahana, D.D.; Ghuman, S.; Wilson, H.P.; Wilson, J.; Kim, S.C.J.; Lagishetty, V.; Jacobs, J.P.; Sinha-Hikim, A.P.; Friedman, T.C. Unhealthy Lifestyle and Gut Dysbiosis: A Better Understanding of the Effects of Poor Diet and Nicotine on the Intestinal Microbiome. Front. Endocrinol. 2021, 12, 667066. [Google Scholar] [CrossRef] [PubMed]
  15. Danese, S.; Fiocchi, C. Ulcerative colitis. New Engl. J. Med. 2011, 365, 1713–1725. [Google Scholar] [CrossRef]
  16. Ananthakrishnan, A.N. Environmental risk factors for inflammatory bowel diseases: A review. Dig. Dis. Sci. 2015, 60, 290–298. [Google Scholar] [CrossRef] [PubMed]
  17. Ramos, G.P.; Papadakis, K.A. Mechanisms of Disease: Inflammatory Bowel Diseases. Mayo Clin. Proc. 2019, 94, 155–165. [Google Scholar] [CrossRef] [PubMed]
  18. Larabi, A.; Barnich, N.; Nguyen, H.T.T. Emerging Role of Exosomes in Diagnosis and Treatment of Infectious and Inflammatory Bowel Diseases. Cells 2020, 9, 1111. [Google Scholar] [CrossRef] [PubMed]
  19. Bunn, S.K.; Bisset, W.M.; Main, M.J.; Gray, E.S.; Olson, S.; Golden, B.E. Fecal calprotectin: Validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2001, 33, 14–22. [Google Scholar]
  20. Gundersen, M.D.; Goll, R.; Fenton, C.G.; Anderssen, E.; Sørbye, S.W.; Florholmen, J.R.; Paulssen, R.H. Fibrosis Mediators in the Colonic Mucosa of Acute and Healed Ulcerative Colitis. Clin. Transl. Gastroenterol. 2019, 10, e00082. [Google Scholar] [CrossRef]
  21. Molodecky, N.A.; Soon, I.S.; Rabi, D.M.; Ghali, W.A.; Ferris, M.; Chernoff, G.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Barkema, H.W.; et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142, 46–54.e42; quiz e30. [Google Scholar] [CrossRef] [PubMed]
  22. Bernstein, C.N.; Wajda, A.; Svenson, L.W.; MacKenzie, A.; Koehoorn, M.; Jackson, M.; Fedorak, R.; Israel, D.; Blanchard, J.F. The epidemiology of inflammatory bowel disease in Canada: A population-based study. Am. J. Gastroenterol. 2006, 101, 1559–1568. [Google Scholar] [CrossRef] [PubMed]
  23. Shivananda, S.; Lennard-Jones, J.; Logan, R.; Fear, N.; Price, A.; Carpenter, L.; van Blankenstein, M. Incidence of inflammatory bowel disease across Europe: Is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996, 39, 690–697. [Google Scholar] [CrossRef]
  24. Cosnes, J.; Gower-Rousseau, C.; Seksik, P.; Cortot, A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011, 140, 1785–1794. [Google Scholar] [CrossRef] [PubMed]
  25. Bengtson, M.B.; Solberg, C.; Aamodt, G.; Sauar, J.; Jahnsen, J.; Moum, B.; Lygren, I.; Vatn, M.H. Familial aggregation in Crohn’s disease and ulcerative colitis in a Norwegian population-based cohort followed for ten years. J. Crohns Colitis 2009, 3, 92–99. [Google Scholar] [CrossRef] [PubMed]
  26. Loftus, C.G.; Loftus, E.V., Jr.; Harmsen, W.S.; Zinsmeister, A.R.; Tremaine, W.J.; Melton, L.J., 3rd; Sandborn, W.J. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm. Bowel Dis. 2007, 13, 254–261. [Google Scholar] [CrossRef] [PubMed]
  27. Ng, S.C.; Tang, W.; Ching, J.Y.; Wong, M.; Chow, C.M.; Hui, A.J.; Wong, T.C.; Leung, V.K.; Tsang, S.W.; Yu, H.H.; et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study. Gastroenterology 2013, 145, 158–165.e152. [Google Scholar] [CrossRef] [PubMed]
  28. Sood, A.; Midha, V.; Sood, N.; Bhatia, A.S.; Avasthi, G. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut 2003, 52, 1587–1590. [Google Scholar] [CrossRef] [PubMed]
  29. Tozun, N.; Atug, O.; Imeryuz, N.; Hamzaoglu, H.O.; Tiftikci, A.; Parlak, E.; Dagli, U.; Ulker, A.; Hulagu, S.; Akpinar, H.; et al. Clinical characteristics of inflammatory bowel disease in Turkey: A multicenter epidemiologic survey. J. Clin. Gastroenterol. 2009, 43, 51–57. [Google Scholar] [CrossRef]
  30. Victoria, C.R.; Sassak, L.Y.; Nunes, H.R. Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of São Paulo State, Brazil. Arq. Gastroenterol. 2009, 46, 20–25. [Google Scholar] [CrossRef]
  31. Sood, A.; Midha, V.; Makharia, G.K.; Ahuja, V.; Singal, D.; Goswami, P.; Tandon, R.K. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin. Gastroenterol. Hepatol. 2009, 7, 1202–1209.e1201. [Google Scholar] [PubMed]
  32. Loftus, E.V., Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004, 126, 1504–1517. [Google Scholar] [CrossRef] [PubMed]
  33. Fakhoury, M.; Negrulj, R.; Mooranian, A.; Al-Salami, H. Inflammatory bowel disease: Clinical aspects and treatments. J. Inflamm. Res. 2014, 7, 113–120. [Google Scholar] [CrossRef] [PubMed]
  34. Chan, W.; Chen, A.; Tiao, D.; Selinger, C.; Leong, R. Medication adherence in inflammatory bowel disease. Intest. Res. 2017, 15, 434–445. [Google Scholar] [CrossRef] [PubMed]
  35. Langholz, E. Current trends in inflammatory bowel disease: The natural history. Therap. Adv. Gastroenterol. 2010, 3, 77–86. [Google Scholar] [CrossRef] [PubMed]
  36. Gryaznova, M.V.; Solodskikh, S.A.; Panevina, A.V.; Syromyatnikov, M.Y.; Dvoretskaya, Y.D.; Sviridova, T.N.; Popov, E.S.; Popov, V.N. Study of microbiome changes in patients with ulcerative colitis in the Central European part of Russia. Heliyon 2021, 7, e06432. [Google Scholar] [CrossRef] [PubMed]
  37. Vedamurthy, A.; Ananthakrishnan, A.N. Influence of Environmental Factors in the Development and Outcomes of Inflammatory Bowel Disease. Gastroenterol. Hepatol. 2019, 15, 72–82. [Google Scholar]
  38. Losurdo, G.; La Fortezza, R.F.; Iannone, A.; Contaldo, A.; Barone, M.; Ierardi, E.; Di Leo, A.; Principi, M. Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study. World J. Gastroenterol. 2020, 26, 7528–7537. [Google Scholar] [CrossRef] [PubMed]
  39. Santos, M.P.C.; Gomes, C.; Torres, J. Familial and ethnic risk in inflammatory bowel disease. Ann. Gastroenterol. 2018, 31, 14–23. [Google Scholar] [CrossRef]
  40. Roozendaal, C.; Zhao, M.H.; Horst, G.; Lockwood, C.M.; Kleibeuker, J.H.; Limburg, P.C.; Nelis, G.F.; Kallenberg, C.G. Catalase and alpha-enolase: Two novel granulocyte autoantigens in inflammatory bowel disease (IBD). Clin. Exp. Immunol. 1998, 112, 10–16. [Google Scholar]
  41. Ananthakrishnan, A.N. Epidemiology and risk factors for IBD. Nat. Rev. Gastroenterol. Hepatol. 2015, 12, 205–217. [Google Scholar] [CrossRef] [PubMed]
  42. Parkes, M. Debate session: So what causes inflammatory bowel disease? It’s all in the genes. J. Gastroenterol. Hepatol. 2018, 33 (Suppl. S3), 23. [Google Scholar] [CrossRef] [PubMed]
  43. Dethlefsen, L.; Huse, S.; Sogin, M.L.; Relman, D.A. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 2008, 6, e280. [Google Scholar] [CrossRef] [PubMed]
  44. Gilat, T.; Hacohen, D.; Lilos, P.; Langman, M.J. Childhood factors in ulcerative colitis and Crohn’s disease. An international cooperative study. Scand J. Gastroenterol. 1987, 22, 1009–1024. [Google Scholar] [CrossRef] [PubMed]
  45. Legaki, E.; Gazouli, M. Influence of environmental factors in the development of inflammatory bowel diseases. World J. Gastrointest. Pharmacol. Ther. 2016, 7, 112–125. [Google Scholar] [CrossRef]
  46. Tuvlin, J.A.; Raza, S.S.; Bracamonte, S.; Julian, C.; Hanauer, S.B.; Nicolae, D.L.; King, A.C.; Cho, J.H. Smoking and inflammatory bowel disease: Trends in familial and sporadic cohorts. Inflamm. Bowel Dis. 2007, 13, 573–579. [Google Scholar] [CrossRef] [PubMed]
  47. Biedermann, L.; Zeitz, J.; Mwinyi, J.; Sutter-Minder, E.; Rehman, A.; Ott, S.J.; Steurer-Stey, C.; Frei, A.; Frei, P.; Scharl, M.; et al. Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans. PLoS ONE 2013, 8, e59260. [Google Scholar] [CrossRef] [PubMed]
  48. Parkes, G.C.; Whelan, K.; Lindsay, J.O. Smoking in inflammatory bowel disease: Impact on disease course and insights into the aetiology of its effect. J. Crohns Colitis 2014, 8, 717–725. [Google Scholar] [CrossRef]
  49. Rice, K.M.; Walker, E.M., Jr.; Wu, M.; Gillette, C.; Blough, E.R. Environmental mercury and its toxic effects. J. Prev. Med. Public Health 2014, 47, 74–83. [Google Scholar] [CrossRef]
  50. Mawdsley, J.E.; Rampton, D.S. Psychological stress in IBD: New insights into pathogenic and therapeutic implications. Gut 2005, 54, 1481–1491. [Google Scholar] [CrossRef]
  51. Goodhand, J.R.; Wahed, M.; Mawdsley, J.E.; Farmer, A.D.; Aziz, Q.; Rampton, D.S. Mood disorders in inflammatory bowel disease: Relation to diagnosis, disease activity, perceived stress, and other factors. Inflamm. Bowel Dis. 2012, 18, 2301–2309. [Google Scholar] [CrossRef] [PubMed]
  52. Reber, S.O. Stress and animal models of inflammatory bowel disease—An update on the role of the hypothalamo-pituitary-adrenal axis. Psychoneuroendocrinology 2012, 37, 1–19. [Google Scholar] [CrossRef] [PubMed]
  53. Navaneethan, U.; Shen, B. Pros and cons of medical management of ulcerative colitis. Clin. Colon Rectal. Surg. 2010, 23, 227–238. [Google Scholar] [CrossRef] [PubMed]
  54. Ennaifer, R.; Elleuch, N.; Cheikh, M.; Hefaiedh, R.; Romdhane, H.; Ben Nejma, H.; Belhadj, N. Risk factors of psychological disorders in inflammatory bowel disease in a tunisian survey. Results of a cross-sectional study. Tunis Med. 2014, 92, 723–726. [Google Scholar] [PubMed]
  55. Cherry, L.N.; Yunker, N.S.; Lambert, E.R.; Vaughan, D.; Lowe, D.K. Vedolizumab: An α4β7 integrin antagonist for ulcerative colitis and Crohn’s disease. Ther. Adv. Chronic. Dis. 2015, 6, 224–233. [Google Scholar] [CrossRef] [PubMed]
  56. Feagan, B.G.; Rutgeerts, P.; Sands, B.E.; Hanauer, S.; Colombel, J.F.; Sandborn, W.J.; Van Assche, G.; Axler, J.; Kim, H.J.; Danese, S.; et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New Engl. J. Med. 2013, 369, 699–710. [Google Scholar] [CrossRef] [PubMed]
  57. Singh, M.; George, A.K.; Homme, R.P.; Majumder, A.; Laha, A.; Metreveli, N.; Pushpakumar, S.B.; Tyagi, S.C. Probiotic supplementation mitigates vascular remodeling in the retina. FASEB J. 2019, 33, 484.11. [Google Scholar] [CrossRef]
  58. Singh, M.; George, A.K.; Homme, R.P.; Majumder, A.; Metreveli, N.; Laha, A.; Pushpakumar, S.B.; Tyagi, S.C. Studying Long-term Effects of a Probiotic on Neuroretinal Health. Investig. Ophthalmol. Vis. Sci. 2019, 60, 4885. [Google Scholar]
  59. Majumder, A.; Singh, M.; George, A.K.; Homme, R.P.; Metreveli, N.; Tyagi, S.C. Lactobacillus rhamnosus GG improves skeletal muscle fatigability in a mouse model of hyperhomocysteinemia. FASEB J. 2019, 33, 592.12. [Google Scholar] [CrossRef]
  60. George, A.K.; Singh, M.; Majumder, A.; Homme, R.P.; Metreveli, N.; Pushpakumar, S.B.; Tyagi, S.C. Hyperhomocysteinemia and the effects of Lactobacillus rhamnosus GG on cardiac functions in CBS+/− mice. FASEB J. 2019, 33, 531.37. [Google Scholar] [CrossRef]
  61. Cheng, F.S.; Pan, D.; Chang, B.; Jiang, M.; Sang, L.X. Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases. World J. Clin. Cases 2020, 8, 1361–1384. [Google Scholar] [PubMed]
  62. Dai, C.; Zheng, C.Q.; Meng, F.J.; Zhou, Z.; Sang, L.X.; Jiang, M. VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF-κB pathway in rat model of DSS-induced colitis. Mol. Cell Biochem. 2013, 374, 1–11. [Google Scholar] [PubMed]
  63. Tursi, A.; Brandimarte, G.; Papa, A.; Giglio, A.; Elisei, W.; Giorgetti, G.M.; Forti, G.; Morini, S.; Hassan, C.; Pistoia, M.A.; et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: A double-blind, randomized, placebo-controlled study. Am. J. Gastroenterol. 2010, 105, 2218–2227. [Google Scholar] [PubMed]
  64. Jiang, Y.; Zhang, Z.G.; Qi, F.X.; Zhang, Y.; Han, T. Comparison of maintenance effect of probiotics and aminosalicylates on ulcerative colitis: A meta-analysis of randomized controlled trials. Chronic Dis. Transl. Med. 2016, 2, 34–41. [Google Scholar] [CrossRef] [PubMed]
  65. Liu, S.; Eisenstein, S. State-of-the-art surgery for ulcerative colitis. Langenbecks Arch. Surg. 2021, 406, 1751–1761. [Google Scholar] [CrossRef]
  66. Boaduo, N.K.; Katerere, D.; Eloff, J.N.; Naidoo, V. Evaluation of six plant species used traditionally in the treatment and control of diabetes mellitus in South Africa using in vitro methods. Pharm. Biol. 2014, 52, 756–761. [Google Scholar] [CrossRef] [PubMed]
  67. Kornbluth, A.; Sachar, D.B. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol. 2010, 105, 501–523; quiz 524. [Google Scholar] [CrossRef] [PubMed]
  68. Zhang, X.; Ishikawa, D.; Ohkusa, T.; Fukuda, S.; Nagahara, A. Hot topics on fecal microbiota transplantation for the treatment of inflammatory bowel disease. Front. Med. 2022, 9, 1068567. [Google Scholar] [CrossRef] [PubMed]
  69. Dignass, A.; Lindsay, J.O.; Sturm, A.; Windsor, A.; Colombel, J.F.; Allez, M.; D’Haens, G.; D’Hoore, A.; Mantzaris, G.; Novacek, G.; et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: Current management. J. Crohns Colitis 2012, 6, 991–1030. [Google Scholar] [CrossRef]
  70. Zhang, Y.; Chen, R.; Zhang, D.; Qi, S.; Liu, Y. Metabolite interactions between host and microbiota during health and disease: Which feeds the other? Biomed. Pharmacother. 2023, 160, 114295. [Google Scholar] [CrossRef]
  71. Bull, M.J.; Plummer, N.T. Part 1: The Human Gut Microbiome in Health and Disease. Integr. Med. 2014, 13, 17–22. [Google Scholar]
  72. Laha, A.; Majumder, A.; Singh, M.; Tyagi, S.C. Connecting homocysteine and obesity through pyroptosis, gut microbiome, epigenetics, peroxisome proliferator-activated receptor γ, and zinc finger protein 407. Can. J. Physiol. Pharmacol. 2018, 96, 971–976. [Google Scholar] [CrossRef]
  73. Huurre, A.; Kalliomäki, M.; Rautava, S.; Rinne, M.; Salminen, S.; Isolauri, E. Mode of delivery-effects on gut microbiota and humoral immunity. Neonatology 2008, 93, 236–240. [Google Scholar] [CrossRef] [PubMed]
  74. Church, D.L.; Cerutti, L.; Gürtler, A.; Griener, T.; Zelazny, A.; Emler, S. Performance and Application of 16S rRNA Gene Cycle Sequencing for Routine Identification of Bacteria in the Clinical Microbiology Laboratory. Clin. Microbiol. Rev. 2020, 33, e00053-19. [Google Scholar] [CrossRef]
  75. Thursby, E.; Juge, N. Introduction to the human gut microbiota. Biochem. J. 2017, 474, 1823–1836. [Google Scholar] [CrossRef]
  76. Hugon, P.; Dufour, J.C.; Colson, P.; Fournier, P.E.; Sallah, K.; Raoult, D. A comprehensive repertoire of prokaryotic species identified in human beings. Lancet Infect. Dis. 2015, 15, 1211–1219. [Google Scholar] [CrossRef]
  77. Ramakrishna, B.S. The Normal Bacterial Flora of the Human Intestine and Its Regulation. J. Clin. Gastroenterol. 2007, 41, S2–S6. [Google Scholar] [CrossRef]
  78. Johansson, M.E.; Gustafsson, J.K.; Holmén-Larsson, J.; Jabbar, K.S.; Xia, L.; Xu, H.; Ghishan, F.K.; Carvalho, F.A.; Gewirtz, A.T.; Sjövall, H.; et al. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut 2014, 63, 281–291. [Google Scholar] [CrossRef] [PubMed]
  79. George, A.K.; Homme, R.P.; Majumder, A.; Tyagi, S.C.; Singh, M. Effect of MMP-9 gene knockout on retinal vascular form and function. Physiol. Genom. 2019, 51, 613–622. [Google Scholar] [CrossRef]
  80. Johansson, M.E.; Jakobsson, H.E.; Holmén-Larsson, J.; Schütte, A.; Ermund, A.; Rodríguez-Piñeiro, A.M.; Arike, L.; Wising, C.; Svensson, F.; Bäckhed, F.; et al. Normalization of Host Intestinal Mucus Layers Requires Long-Term Microbial Colonization. Cell Host Microbe 2015, 18, 582–592. [Google Scholar] [CrossRef]
  81. Juge, N. Microbial adhesins to gastrointestinal mucus. Trends Microbiol. 2012, 20, 30–39. [Google Scholar] [CrossRef] [PubMed]
  82. Tailford, L.E.; Owen, C.D.; Walshaw, J.; Crost, E.H.; Hardy-Goddard, J.; Le Gall, G.; de Vos, W.M.; Taylor, G.L.; Juge, N. Discovery of intramolecular trans-sialidases in human gut microbiota suggests novel mechanisms of mucosal adaptation. Nat. Commun. 2015, 6, 7624. [Google Scholar] [CrossRef]
  83. Constante, M.; Fragoso, G.; Lupien-Meilleur, J.; Calvé, A.; Santos, M.M. Iron Supplements Modulate Colon Microbiota Composition and Potentiate the Protective Effects of Probiotics in Dextran Sodium Sulfate-induced Colitis. Inflamm. Bowel Dis. 2017, 23, 753–766. [Google Scholar] [CrossRef] [PubMed]
  84. Ni, J.; Wu, G.D.; Albenberg, L.; Tomov, V.T. Gut microbiota and IBD: Causation or correlation? Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 573–584. [Google Scholar] [CrossRef]
  85. Machiels, K.; Joossens, M.; Sabino, J.; De Preter, V.; Arijs, I.; Eeckhaut, V.; Ballet, V.; Claes, K.; Van Immerseel, F.; Verbeke, K.; et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 2014, 63, 1275–1283. [Google Scholar] [CrossRef] [PubMed]
  86. Tang, Y.H.; Liu, H.C.; Song, G.; Wu, T.T.; Zhao, Y.; Shi, L.J. A case-control study on the association of intestinal flora with ulcerative colitis. AMB Express 2021, 11, 106. [Google Scholar] [CrossRef]
  87. Ponnusamy, K.; Choi, J.N.; Kim, J.; Lee, S.Y.; Lee, C.H. Microbial community and metabolomic comparison of irritable bowel syndrome faeces. J. Med. Microbiol. 2011, 60, 817–827. [Google Scholar] [CrossRef]
  88. Frank, D.N.; St Amand, A.L.; Feldman, R.A.; Boedeker, E.C.; Harpaz, N.; Pace, N.R. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl. Acad. Sci. USA 2007, 104, 13780–13785. [Google Scholar] [CrossRef]
  89. Karczewski, J.; Troost, F.J.; Konings, I.; Dekker, J.; Kleerebezem, M.; Brummer, R.J.; Wells, J.M. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 298, G851–G859. [Google Scholar] [CrossRef]
  90. Hou, J.K.; Abraham, B.; El-Serag, H. Dietary intake and risk of developing inflammatory bowel disease: A systematic review of the literature. Am. J. Gastroenterol. 2011, 106, 563–573. [Google Scholar] [CrossRef]
  91. Cordain, L.; Eaton, S.B.; Sebastian, A.; Mann, N.; Lindeberg, S.; Watkins, B.A.; O’Keefe, J.H.; Brand-Miller, J. Origins and evolution of the Western diet: Health implications for the 21st century. Am. J. Clin. Nutr. 2005, 81, 341–354. [Google Scholar] [CrossRef] [PubMed]
  92. Rakhra, V.; Galappaththy, S.L.; Bulchandani, S.; Cabandugama, P.K. Obesity and the Western Diet: How We Got Here. Mo Med. 2020, 117, 536–538. [Google Scholar] [PubMed]
  93. Salas-Salvadó, J.; Becerra-Tomás, N.; García-Gavilán, J.F.; Bulló, M.; Barrubés, L. Mediterranean Diet and Cardiovascular Disease Prevention: What Do We Know? Prog. Cardiovasc. Dis. 2018, 61, 62–67. [Google Scholar] [CrossRef] [PubMed]
  94. Godos, J.; Scazzina, F.; Paternò Castello, C.; Giampieri, F.; Quiles, J.L.; Briones Urbano, M.; Battino, M.; Galvano, F.; Iacoviello, L.; de Gaetano, G.; et al. Underrated aspects of a true Mediterranean diet: Understanding traditional features for worldwide application of a “Planeterranean” diet. J. Transl. Med. 2024, 22, 294. [Google Scholar] [CrossRef] [PubMed]
  95. Chun, Y.J.; Sohn, S.K.; Song, H.K.; Lee, S.M.; Youn, Y.H.; Lee, S.; Park, H. Associations of colorectal cancer incidence with nutrient and food group intakes in korean adults: A case-control study. Clin. Nutr. Res. 2015, 4, 110–123. [Google Scholar] [CrossRef] [PubMed]
  96. Weaver, C.M.; Dwyer, J.; Fulgoni, V.L., 3rd; King, J.C.; Leveille, G.A.; MacDonald, R.S.; Ordovas, J.; Schnakenberg, D. Processed foods: Contributions to nutrition. Am. J. Clin. Nutr. 2014, 99, 1525–1542. [Google Scholar] [CrossRef] [PubMed]
  97. Bustamante-Sanchez, A.; Villegas-Mora, B.E.; Martínez-Guardado, I.; Tornero-Aguilera, J.F.; Ardigò, L.P.; Nobari, H.; Clemente-Suárez, V.J. Physical activity and nutritional pattern related to maturation and development. Sustainability 2022, 14, 16958. [Google Scholar] [CrossRef]
  98. Rizzo, D.M.; Lichtveld, M.; Mazet, J.A.K.; Togami, E.; Miller, S.A. Plant health and its effects on food safety and security in a One Health framework: Four case studies. One Health Outlook 2021, 3, 6. [Google Scholar] [CrossRef] [PubMed]
  99. Momtaz, M.; Bubli, S.Y.; Khan, M.S. Mechanisms and Health Aspects of Food Adulteration: A Comprehensive Review. Foods 2023, 12, 199. [Google Scholar] [CrossRef]
  100. Schell, L.M.; Gallo, M.V.; Cook, K. What’s NOT to eat--food adulteration in the context of human biology. Am. J. Hum. Biol. 2012, 24, 139–148. [Google Scholar] [CrossRef]
  101. Murphy, S.P.; Allen, L.H. Nutritional importance of animal source foods. J. Nutr. 2003, 133, 3932s–3935s. [Google Scholar] [CrossRef] [PubMed]
  102. Beal, T.; Gardner, C.D.; Herrero, M.; Iannotti, L.L.; Merbold, L.; Nordhagen, S.; Mottet, A. Friend or Foe? The Role of Animal-Source Foods in Healthy and Environmentally Sustainable Diets. J. Nutr. 2023, 153, 409–425. [Google Scholar] [CrossRef] [PubMed]
  103. Majumder, A.; Doshi, B.; Sheth, F.; Patel, M.; Shah, N.; Premal, T.; Vaidya, R.; Sheth, J. Association of Vitamin D 3 levels with glycemic control in Type 2 diabetes subjects from Gujarati population-India. Mol. Cytogenet. 2014, 7, 1. [Google Scholar] [CrossRef]
  104. Brown, K.; DeCoffe, D.; Molcan, E.; Gibson, D.L. Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Nutrients 2012, 4, 1095–1119. [Google Scholar] [CrossRef] [PubMed]
  105. Radziszewska, M.; Smarkusz-Zarzecka, J.; Ostrowska, L.; Pogodziński, D. Nutrition and Supplementation in Ulcerative Colitis. Nutrients 2022, 14, 2469. [Google Scholar] [CrossRef] [PubMed]
  106. Li, F.; Liu, X.; Wang, W.; Zhang, D. Consumption of vegetables and fruit and the risk of inflammatory bowel disease: A meta-analysis. Eur. J. Gastroenterol. Hepatol. 2015, 27, 623–630. [Google Scholar] [CrossRef] [PubMed]
  107. Nie, J.Y.; Zhao, Q. Beverage consumption and risk of ulcerative colitis: Systematic review and meta-analysis of epidemiological studies. Medicine 2017, 96, e9070. [Google Scholar] [CrossRef] [PubMed]
  108. De Filippo, C.; Cavalieri, D.; Di Paola, M.; Ramazzotti, M.; Poullet, J.B.; Massart, S.; Collini, S.; Pieraccini, G.; Lionetti, P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl. Acad. Sci. USA 2010, 107, 14691–14696. [Google Scholar] [CrossRef] [PubMed]
  109. Fan, W.; Huo, G.; Li, X.; Yang, L.; Duan, C. Impact of diet in shaping gut microbiota revealed by a comparative study in infants during the six months of life. J. Microbiol. Biotechnol. 2014, 24, 133–143. [Google Scholar] [CrossRef]
  110. Agus, A.; Denizot, J.; Thévenot, J.; Martinez-Medina, M.; Massier, S.; Sauvanet, P.; Bernalier-Donadille, A.; Denis, S.; Hofman, P.; Bonnet, R.; et al. Western diet induces a shift in microbiota composition enhancing susceptibility to Adherent-Invasive E. coli infection and intestinal inflammation. Sci. Rep. 2016, 6, 19032. [Google Scholar] [CrossRef]
  111. Neis, E.P.; van Eijk, H.M.; Lenaerts, K.; Olde Damink, S.W.; Blaak, E.E.; Dejong, C.H.; Rensen, S.S. Distal versus proximal intestinal short-chain fatty acid release in man. Gut 2019, 68, 764–765. [Google Scholar] [CrossRef] [PubMed]
  112. Sun, M.; Wu, W.; Liu, Z.; Cong, Y. Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases. J. Gastroenterol. 2017, 52, 1–8. [Google Scholar] [CrossRef] [PubMed]
  113. Reddavide, R.; Rotolo, O.; Caruso, M.G.; Stasi, E.; Notarnicola, M.; Miraglia, C.; Nouvenne, A.; Meschi, T.; De’ Angelis, G.L.; Di Mario, F.; et al. The role of diet in the prevention and treatment of Inflammatory Bowel Diseases. Acta Biomed. 2018, 89, 60–75. [Google Scholar] [PubMed]
  114. Sugihara, K.; Morhardt, T.L.; Kamada, N. The Role of Dietary Nutrients in Inflammatory Bowel Disease. Front. Immunol. 2018, 9, 3183. [Google Scholar] [CrossRef] [PubMed]
  115. Koleva, P.; Ketabi, A.; Valcheva, R.; Gänzle, M.G.; Dieleman, L.A. Chemically defined diet alters the protective properties of fructo-oligosaccharides and isomalto-oligosaccharides in HLA-B27 transgenic rats. PLoS ONE 2014, 9, e111717. [Google Scholar] [CrossRef]
  116. Nicholson, J.K.; Holmes, E.; Kinross, J.; Burcelin, R.; Gibson, G.; Jia, W.; Pettersson, S. Host-gut microbiota metabolic interactions. Science 2012, 336, 1262–1267. [Google Scholar] [CrossRef] [PubMed]
  117. Krautkramer, K.A.; Kreznar, J.H.; Romano, K.A.; Vivas, E.I.; Barrett-Wilt, G.A.; Rabaglia, M.E.; Keller, M.P.; Attie, A.D.; Rey, F.E.; Denu, J.M. Diet-Microbiota Interactions Mediate Global Epigenetic Programming in Multiple Host Tissues. Mol. Cell 2016, 64, 982–992. [Google Scholar] [CrossRef] [PubMed]
  118. Majumder, A.; Behera, J.; Jeremic, N.; Tyagi, S.C. Hypermethylation: Causes and Consequences in Skeletal Muscle Myopathy. J. Cell Biochem. 2017, 118, 2108–2117. [Google Scholar] [CrossRef]
  119. Majumder, A.; Singh, M.; George, A.K.; Homme, R.P.; Laha, A.; Tyagi, S.C. Remote ischemic conditioning as a cytoprotective strategy in vasculopathies during hyperhomocysteinemia: An emerging research perspective. J. Cell Biochem. 2019, 120, 77–92. [Google Scholar] [CrossRef]
  120. Majumder, A. Targeting Homocysteine and Hydrogen Sulfide Balance as Future Therapeutics in Cancer Treatment. Antioxidants 2023, 12, 1520. [Google Scholar] [CrossRef]
  121. George, A.K.; Majumder, A.; Ice, H.; Homme, R.P.; Eyob, W.; Tyagi, S.C.; Singh, M. Genes and genetics in hyperhomocysteinemia and the “1-carbon metabolism”: Implications for retinal structure and eye functions. Can. J. Physiol. Pharmacol. 2020, 98, 51–60. [Google Scholar] [CrossRef]
  122. Kovacheva, V.P.; Mellott, T.J.; Davison, J.M.; Wagner, N.; Lopez-Coviella, I.; Schnitzler, A.C.; Blusztajn, J.K. Gestational choline deficiency causes global and Igf2 gene DNA hypermethylation by up-regulation of Dnmt1 expression. J. Biol. Chem. 2007, 282, 31777–31788. [Google Scholar] [CrossRef] [PubMed]
  123. Majumder, A.; Singh, M.; George, A.K.; Tyagi, S.C. Restoration of skeletal muscle homeostasis by hydrogen sulfide during hyperhomocysteinemia-mediated oxidative/ER stress condition (1). Can. J. Physiol. Pharmacol. 2019, 97, 441–456. [Google Scholar] [CrossRef]
  124. Majumder, A. Exploiting Methionine Addiction as a Potential Treatment Strategy for Cancer. Nov. Asp. Chem. Biochem. 2023, 8, 133–181. [Google Scholar]
  125. Strozzi, G.P.; Mogna, L. Quantification of folic acid in human feces after administration of Bifidobacterium probiotic strains. J. Clin. Gastroenterol. 2008, 42 Pt 2 (Suppl. S3), S179–S184. [Google Scholar] [CrossRef] [PubMed]
  126. Rossi, M.; Amaretti, A.; Raimondi, S. Folate production by probiotic bacteria. Nutrients 2011, 3, 118–134. [Google Scholar] [CrossRef] [PubMed]
  127. Sarkar, S.; Abujamra, A.L.; Loew, J.E.; Forman, L.W.; Perrine, S.P.; Faller, D.V. Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling. Anticancer. Res. 2011, 31, 2723–2732. [Google Scholar]
  128. Majumder, A.; Singh, M.; Tyagi, S.C. Post-menopausal breast cancer: From estrogen to androgen receptor. Oncotarget 2017, 8, 102739–102758. [Google Scholar] [CrossRef]
  129. Bernstein, B.E.; Meissner, A.; Lander, E.S. The mammalian epigenome. Cell 2007, 128, 669–681. [Google Scholar] [CrossRef]
  130. Paul, B.; Barnes, S.; Demark-Wahnefried, W.; Morrow, C.; Salvador, C.; Skibola, C.; Tollefsbol, T.O. Influences of diet and the gut microbiome on epigenetic modulation in cancer and other diseases. Clin. Epigenetics 2015, 7, 112. [Google Scholar] [CrossRef]
  131. Majumder, A. Effects of Hydrogen Sulfide in Hyperhomocysteinemia-Mediated Skeletal Muscle Myopathy. Doctoral Dissertation, University of Louisville, Louisville, KY, USA, 2018. [Google Scholar]
  132. Thomas, S.P.; Denu, J.M. Short-chain fatty acids activate acetyltransferase p300. eLife 2021, 10, e72171. [Google Scholar] [CrossRef] [PubMed]
  133. Stein, R.A.; Riber, L. Epigenetic effects of short-chain fatty acids from the large intestine on host cells. Microlife 2023, 4, uqad032. [Google Scholar] [CrossRef] [PubMed]
  134. George, A.K.; Master, K.; Majumder, A.; Homme, R.P.; Laha, A.; Sandhu, H.S.; Tyagi, S.C.; Singh, M. Circular RNAs constitute an inherent gene regulatory axis in the mammalian eye and brain (1). Can. J. Physiol. Pharmacol. 2019, 97, 463–472. [Google Scholar] [CrossRef] [PubMed]
  135. Singh, M.; George, A.K.; Homme, R.P.; Majumder, A.; Laha, A.; Sandhu, H.S.; Tyagi, S.C. Circular RNAs profiling in the cystathionine-β-synthase mutant mouse reveals novel gene targets for hyperhomocysteinemia induced ocular disorders. Exp. Eye Res. 2018, 174, 80–92. [Google Scholar] [CrossRef]
  136. Singh, M.; George, A.K.; Homme, R.P.; Majumder, A.; Laha, A.; Sandhu, H.S.; Tyagi, S.C. Expression Analysis of the Circular RNA Molecules in the Human Retinal Cells Treated with Homocysteine. Curr. Eye Res. 2019, 44, 287–293. [Google Scholar] [CrossRef] [PubMed]
  137. Liang, L.; Ai, L.; Qian, J.; Fang, J.Y.; Xu, J. Long noncoding RNA expression profiles in gut tissues constitute molecular signatures that reflect the types of microbes. Sci. Rep. 2015, 5, 11763. [Google Scholar] [CrossRef] [PubMed]
  138. Dempsey, J.; Zhang, A.; Cui, J.Y. Coordinate regulation of long non-coding RNAs and protein-coding genes in germ-free mice. BMC Genom. 2018, 19, 834. [Google Scholar] [CrossRef] [PubMed]
  139. Virtue, A.T.; McCright, S.J.; Wright, J.M.; Jimenez, M.T.; Mowel, W.K.; Kotzin, J.J.; Joannas, L.; Basavappa, M.G.; Spencer, S.P.; Clark, M.L.; et al. The gut microbiota regulates white adipose tissue inflammation and obesity via a family of microRNAs. Sci. Transl. Med. 2019, 11, eaav1892. [Google Scholar] [CrossRef]
  140. Owczarek, D.; Rodacki, T.; Domagała-Rodacka, R.; Cibor, D.; Mach, T. Diet and nutritional factors in inflammatory bowel diseases. World J. Gastroenterol. 2016, 22, 895–905. [Google Scholar] [CrossRef]
  141. Levine, J.; Ellis, C.J.; Furne, J.K.; Springfield, J.; Levitt, M.D. Fecal hydrogen sulfide production in ulcerative colitis. Am. J. Gastroenterol. 1998, 93, 83–87. [Google Scholar] [CrossRef]
  142. Stummer, N.; Feichtinger, R.G.; Weghuber, D.; Kofler, B.; Schneider, A.M. Role of Hydrogen Sulfide in Inflammatory Bowel Disease. Antioxidants 2023, 12, 1570. [Google Scholar] [CrossRef] [PubMed]
  143. Jowett, S.L.; Seal, C.J.; Pearce, M.S.; Phillips, E.; Gregory, W.; Barton, J.R.; Welfare, M.R. Influence of dietary factors on the clinical course of ulcerative colitis: A prospective cohort study. Gut 2004, 53, 1479–1484. [Google Scholar] [CrossRef] [PubMed]
  144. Beaumont, M.; Andriamihaja, M.; Lan, A.; Khodorova, N.; Audebert, M.; Blouin, J.M.; Grauso, M.; Lancha, L.; Benetti, P.H.; Benamouzig, R.; et al. Detrimental effects for colonocytes of an increased exposure to luminal hydrogen sulfide: The adaptive response. Free Radic. Biol. Med. 2016, 93, 155–164. [Google Scholar] [CrossRef] [PubMed]
  145. Mottawea, W.; Chiang, C.K.; Mühlbauer, M.; Starr, A.E.; Butcher, J.; Abujamel, T.; Deeke, S.A.; Brandel, A.; Zhou, H.; Shokralla, S.; et al. Altered intestinal microbiota-host mitochondria crosstalk in new onset Crohn’s disease. Nat. Commun. 2016, 7, 13419. [Google Scholar] [CrossRef] [PubMed]
  146. Teigen, L.M.; Geng, Z.; Sadowsky, M.J.; Vaughn, B.P.; Hamilton, M.J.; Khoruts, A. Dietary Factors in Sulfur Metabolism and Pathogenesis of Ulcerative Colitis. Nutrients 2019, 11, 931. [Google Scholar] [CrossRef] [PubMed]
  147. Majumder, A.; Singh, M.; Behera, J.; Theilen, N.T.; George, A.K.; Tyagi, N.; Metreveli, N.; Tyagi, S.C. Hydrogen sulfide alleviates hyperhomocysteinemia-mediated skeletal muscle atrophy via mitigation of oxidative and endoplasmic reticulum stress injury. Am. J. Physiol. Cell Physiol. 2018, 315, C609–C622. [Google Scholar] [CrossRef] [PubMed]
  148. Majumder, A.; Singh, M.; George, A.K.; Behera, J.; Tyagi, N.; Tyagi, S.C. Hydrogen sulfide improves postischemic neoangiogenesis in the hind limb of cystathionine-β-synthase mutant mice via PPAR-γ/VEGF axis. Physiol. Rep. 2018, 6, e13858. [Google Scholar] [CrossRef] [PubMed]
  149. George, A.K.; Homme, R.P.; Majumder, A.; Laha, A.; Metreveli, N.; Sandhu, H.S.; Tyagi, S.C.; Singh, M. Hydrogen sulfide intervention in cystathionine-β-synthase mutant mouse helps restore ocular homeostasis. Int. J. Ophthalmol. 2019, 12, 754–764. [Google Scholar] [PubMed]
  150. Hirata, I.; Naito, Y.; Takagi, T.; Mizushima, K.; Suzuki, T.; Omatsu, T.; Handa, O.; Ichikawa, H.; Ueda, H.; Yoshikawa, T. Endogenous hydrogen sulfide is an anti-inflammatory molecule in dextran sodium sulfate-induced colitis in mice. Dig. Dis. Sci. 2011, 56, 1379–1386. [Google Scholar] [CrossRef]
  151. Wallace, J.L.; Vong, L.; McKnight, W.; Dicay, M.; Martin, G.R. Endogenous and exogenous hydrogen sulfide promotes resolution of colitis in rats. Gastroenterology 2009, 137, 569–578.e561. [Google Scholar] [CrossRef]
  152. George, A.K.; Singh, M.; Homme, R.P.; Majumder, A.; Sandhu, H.S.; Tyagi, S.C. A hypothesis for treating inflammation and oxidative stress with hydrogen sulfide during age-related macular degeneration. Int. J. Ophthalmol. 2018, 11, 881–887. [Google Scholar] [PubMed]
  153. Majumder, A.; Singh, M.; George, A.K.; Tyagi, S.C. Hydrogen Sulfide Improves Hyperhomocysteinemia-Mediated Impairment of Angiogenesis in Skeletal Muscle. FASEB J. 2018, 32, 573.72. [Google Scholar] [CrossRef]
  154. Majumder, A.; Behra, J.; Singh, M.; Tyagi, N.; Tyagi, S.C. Hyperhomocysteinemia-Mediated Endoplasmic Reticulum Stress in Skeletal Muscle Dysfunction via JNK/pro-inflammatory Pathway. FASEB J. 2018, 32, 538.34. [Google Scholar] [CrossRef]
  155. Singh, M.; George, A.; Homme, R.P.; Majumder, A.; Tyagi, S. Evaluation of hydrogen sulfide (H2S) effects on visual functions and pyroptosis in a mouse model of hyperhomocysteinemia. Investig. Ophthalmol. Vis. Sci. 2018, 59, 6067. [Google Scholar]
  156. George, A.K.; Singh, M.; Homme, R.P.; Majumder, A.; Tyagi, S. Role of Hydrogen Sulfide (H2S) on Homocysteine Mediated Glutamate Excitotoxicity, Endoplasmic Reticulum Stress and Pyroptosis in Retina. FASEB J. 2018, 32, 748.45. [Google Scholar] [CrossRef]
  157. Qin, M.; Long, F.; Wu, W.; Yang, D.; Huang, M.; Xiao, C.; Chen, X.; Liu, X.; Zhu, Y.Z. Hydrogen sulfide protects against DSS-induced colitis by inhibiting NLRP3 inflammasome. Free. Radic. Biol. Med. 2019, 137, 99–109. [Google Scholar] [CrossRef] [PubMed]
  158. Chen, S.; Bu, D.; Ma, Y.; Zhu, J.; Sun, L.; Zuo, S.; Ma, J.; Li, T.; Chen, Z.; Zheng, Y.; et al. GYY4137 ameliorates intestinal barrier injury in a mouse model of endotoxemia. Biochem. Pharmacol. 2016, 118, 59–67. [Google Scholar] [CrossRef] [PubMed]
  159. Drucker, N.A.; Jensen, A.R.; Te Winkel, J.P.; Markel, T.A. Hydrogen Sulfide Donor GYY4137 Acts Through Endothelial Nitric Oxide to Protect Intestine in Murine Models of Necrotizing Enterocolitis and Intestinal Ischemia. J. Surg. Res. 2019, 234, 294–302. [Google Scholar] [CrossRef]
  160. Parada Venegas, D.; De la Fuente, M.K.; Landskron, G.; González, M.J.; Quera, R.; Dijkstra, G.; Harmsen, H.J.M.; Faber, K.N.; Hermoso, M.A. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Front. Immunol. 2019, 10, 277. [Google Scholar] [CrossRef]
  161. Holleran, G.; Lopetuso, L.; Petito, V.; Graziani, C.; Ianiro, G.; McNamara, D.; Gasbarrini, A.; Scaldaferri, F. The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease. Int. J. Mol. Sci. 2017, 18, 2020. [Google Scholar] [CrossRef]
  162. Homme, R.P.; Singh, M.; Majumder, A.; George, A.K.; Nair, K.; Sandhu, H.S.; Tyagi, N.; Lominadze, D.; Tyagi, S.C. Remodeling of Retinal Architecture in Diabetic Retinopathy: Disruption of Ocular Physiology and Visual Functions by Inflammatory Gene Products and Pyroptosis. Front. Physiol. 2018, 9, 1268. [Google Scholar] [CrossRef] [PubMed]
  163. Pelaseyed, T.; Bergström, J.H.; Gustafsson, J.K.; Ermund, A.; Birchenough, G.M.; Schütte, A.; van der Post, S.; Svensson, F.; Rodríguez-Piñeiro, A.M.; Nyström, E.E.; et al. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunol. Rev. 2014, 260, 8–20. [Google Scholar] [CrossRef] [PubMed]
  164. Elphick, D.A.; Mahida, Y.R. Paneth cells: Their role in innate immunity and inflammatory disease. Gut 2005, 54, 1802–1809. [Google Scholar] [CrossRef] [PubMed]
  165. Roda, G.; Sartini, A.; Zambon, E.; Calafiore, A.; Marocchi, M.; Caponi, A.; Belluzzi, A.; Roda, E. Intestinal epithelial cells in inflammatory bowel diseases. World J. Gastroenterol. 2010, 16, 4264–4271. [Google Scholar] [CrossRef] [PubMed]
  166. Zhang, G.; Ghosh, S. Toll-like receptor-mediated NF-kappaB activation: A phylogenetically conserved paradigm in innate immunity. J. Clin. Investig. 2001, 107, 13–19. [Google Scholar] [CrossRef] [PubMed]
  167. Homme, R.P.; Anewesha, L.; Majumder, A.; George, A.; Singh, M.; Tyagi, S. NF-kB p65 Subunit Inhibitor: JSH-23 Mitigates Diabetic Retinopathy via Reducing Oxidative Stress. FASEB J. 2019, 33, 685.85. [Google Scholar] [CrossRef]
  168. Abreu, M.T.; Fukata, M.; Arditi, M. TLR signaling in the gut in health and disease. J. Immunol. 2005, 174, 4453–4460. [Google Scholar] [CrossRef]
  169. Strober, W.; Fuss, I.J. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011, 140, 1756–1767. [Google Scholar] [CrossRef]
  170. Ahmad, N.; Ansari, M.Y.; Bano, S.; Haqqi, T.M. Imperatorin suppresses IL-1β-induced iNOS expression via inhibiting ERK-MAPK/AP1 signaling in primary human OA chondrocytes. Int. Immunopharmacol. 2020, 85, 106612. [Google Scholar] [CrossRef]
  171. Sanchez-Munoz, F.; Dominguez-Lopez, A.; Yamamoto-Furusho, J.K. Role of cytokines in inflammatory bowel disease. World J. Gastroenterol. 2008, 14, 4280–4288. [Google Scholar] [CrossRef]
  172. Avdagić, N.; Zaćiragić, A.; Babić, N.; Hukić, M.; Seremet, M.; Lepara, O.; Nakaš-Ićindić, E. Nitric oxide as a potential biomarker in inflammatory bowel disease. Bosn J. Basic Med. Sci. 2013, 13, 5–9. [Google Scholar] [CrossRef] [PubMed]
  173. Melgar, S.; Yeung, M.M.; Bas, A.; Forsberg, G.; Suhr, O.; Oberg, A.; Hammarstrom, S.; Danielsson, A.; Hammarstrom, M.L. Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis. Clin. Exp. Immunol. 2003, 134, 127–137. [Google Scholar] [CrossRef] [PubMed]
  174. Dinarello, C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 2009, 27, 519–550. [Google Scholar] [CrossRef]
  175. Aldini, R.; Micucci, M.; Cevenini, M.; Fato, R.; Bergamini, C.; Nanni, C.; Cont, M.; Camborata, C.; Spinozzi, S.; Montagnani, M.; et al. Antiinflammatory effect of phytosterols in experimental murine colitis model: Prevention, induction, remission study. PLoS ONE 2014, 9, e108112. [Google Scholar] [CrossRef] [PubMed]
  176. Sokol, C.L.; Luster, A.D. The chemokine system in innate immunity. Cold Spring Harb. Perspect. Biol. 2015, 7, a016303. [Google Scholar] [CrossRef] [PubMed]
  177. Majumder, A. Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific Discovery to Cures. Cancers 2024, 16, 39. [Google Scholar] [CrossRef] [PubMed]
  178. Atreya, R.; Neurath, M.F. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin. Rev. Allergy Immunol. 2005, 28, 187–196. [Google Scholar] [CrossRef] [PubMed]
  179. Gálvez, J. Role of Th17 Cells in the Pathogenesis of Human IBD. ISRN Inflamm. 2014, 2014, 928461. [Google Scholar] [CrossRef] [PubMed]
  180. Weiner, H.L.; da Cunha, A.P.; Quintana, F.; Wu, H. Oral tolerance. Immunol. Rev. 2011, 241, 241–259. [Google Scholar] [CrossRef]
  181. Silverberg, M.S.; Satsangi, J.; Ahmad, T.; Arnott, I.D.; Bernstein, C.N.; Brant, S.R.; Caprilli, R.; Colombel, J.F.; Gasche, C.; Geboes, K.; et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol. 2005, 19 (Suppl. A), 5a–36a. [Google Scholar] [CrossRef]
  182. Gerlach, K.; Hwang, Y.; Nikolaev, A.; Atreya, R.; Dornhoff, H.; Steiner, S.; Lehr, H.A.; Wirtz, S.; Vieth, M.; Waisman, A.; et al. TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat. Immunol. 2014, 15, 676–686. [Google Scholar] [CrossRef] [PubMed]
  183. Majumder, A.; Tyagi, S.C.; Behera, J. Ciglitazone Prevent Inflammation in Skeletal Muscle Induced by Hyperhomocysteinemia. FASEB J. 2017, 31, 595.98. [Google Scholar] [CrossRef]
  184. Liu, Z.J.; Yadav, P.K.; Su, J.L.; Wang, J.S.; Fei, K. Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. World J. Gastroenterol. 2009, 15, 5784–5788. [Google Scholar] [CrossRef] [PubMed]
  185. Papadakis, K.A.; Targan, S.R. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu. Rev. Med. 2000, 51, 289–298. [Google Scholar] [CrossRef]
  186. Sandborn, W.J.; Hanauer, S.B. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety. Inflamm. Bowel Dis. 1999, 5, 119–133. [Google Scholar] [CrossRef] [PubMed]
  187. Larabi, A.; Barnich, N.; Nguyen, H.T.T. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. Autophagy 2020, 16, 38–51. [Google Scholar] [CrossRef]
  188. Monteleone, G.; Boirivant, M.; Pallone, F.; MacDonald, T.T. TGF-beta1 and Smad7 in the regulation of IBD. Mucosal Immunol. 2008, 1 (Suppl S1), S50–S53. [Google Scholar] [CrossRef] [PubMed]
  189. Ito, R.; Shin-Ya, M.; Kishida, T.; Urano, A.; Takada, R.; Sakagami, J.; Imanishi, J.; Kita, M.; Ueda, Y.; Iwakura, Y.; et al. Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin. Exp. Immunol. 2006, 146, 330–338. [Google Scholar] [CrossRef]
  190. Ghosh, S.; Chaudhary, R.; Carpani, M.; Playford, R. Interfering with interferons in inflammatory bowel disease. Gut 2006, 55, 1071–1073. [Google Scholar] [CrossRef]
  191. Lundgren, B.A.; Rorsman, F.; Portela-Gomes, G.M.; Grimelius, L.; Ekdahl, K.N.; Nilsson, B.; Ekwall, O. Identification of complement C3 as an autoantigen in inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 2010, 22, 429–436. [Google Scholar] [CrossRef]
  192. Kirov, S.; Sasson, A.; Zhang, C.; Chasalow, S.; Dongre, A.; Steen, H.; Stensballe, A.; Andersen, V.; Birkelund, S.; Bennike, T.B. Degradation of the extracellular matrix is part of the pathology of ulcerative colitis. Mol. Omics. 2019, 15, 67–76. [Google Scholar] [CrossRef] [PubMed]
  193. Koelink, P.J.; Overbeek, S.A.; Braber, S.; Morgan, M.E.; Henricks, P.A.; Abdul Roda, M.; Verspaget, H.W.; Wolfkamp, S.C.; te Velde, A.A.; Jones, C.W.; et al. Collagen degradation and neutrophilic infiltration: A vicious circle in inflammatory bowel disease. Gut 2014, 63, 578–587. [Google Scholar] [CrossRef] [PubMed]
  194. Shimshoni, E.; Adir, I.; Afik, R.; Solomonov, I.; Shenoy, A.; Adler, M.; Puricelli, L.; Sabino, F.; Savickas, S.; Mouhadeb, O.; et al. Distinct extracellular-matrix remodeling events precede symptoms of inflammation. Matrix Biol. 2021, 96, 47–68. [Google Scholar] [CrossRef] [PubMed]
  195. Kirkegaard, T.; Hansen, A.; Bruun, E.; Brynskov, J. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn’s disease. Gut 2004, 53, 701–709. [Google Scholar] [CrossRef] [PubMed]
  196. Baugh, M.D.; Perry, M.J.; Hollander, A.P.; Davies, D.R.; Cross, S.S.; Lobo, A.J.; Taylor, C.J.; Evans, G.S. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 1999, 117, 814–822. [Google Scholar] [CrossRef] [PubMed]
  197. Bennike, T.B.; Carlsen, T.G.; Ellingsen, T.; Bonderup, O.K.; Glerup, H.; Bøgsted, M.; Christiansen, G.; Birkelund, S.; Stensballe, A.; Andersen, V. Neutrophil Extracellular Traps in Ulcerative Colitis: A Proteome Analysis of Intestinal Biopsies. Inflamm. Bowel Dis. 2015, 21, 2052–2067. [Google Scholar] [CrossRef] [PubMed]
  198. Gao, Q.; Meijer, M.J.; Kubben, F.J.; Sier, C.F.; Kruidenier, L.; van Duijn, W.; van den Berg, M.; van Hogezand, R.A.; Lamers, C.B.; Verspaget, H.W. Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Dig. Liver Dis. 2005, 37, 584–592. [Google Scholar] [CrossRef] [PubMed]
  199. Lerner, I.; Hermano, E.; Zcharia, E.; Rodkin, D.; Bulvik, R.; Doviner, V.; Rubinstein, A.M.; Ishai-Michaeli, R.; Atzmon, R.; Sherman, Y.; et al. Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J. Clin. Invest. 2011, 121, 1709–1721. [Google Scholar] [CrossRef] [PubMed]
  200. Castaneda, F.E.; Walia, B.; Vijay-Kumar, M.; Patel, N.R.; Roser, S.; Kolachala, V.L.; Rojas, M.; Wang, L.; Oprea, G.; Garg, P.; et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: Central role of epithelial-derived MMP. Gastroenterology 2005, 129, 1991–2008. [Google Scholar] [CrossRef]
  201. Majumder, A. HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer. Cells 2023, 12, 2517. [Google Scholar] [CrossRef]
  202. Majumder, A.; Sandhu, M.; Banerji, D.; Steri, V.; Olshen, A.; Moasser, M.M. The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers. Sci. Rep. 2021, 11, 9091. [Google Scholar] [CrossRef]
  203. Majumder, A.; Steri, V.; Salangsang, F.; Moasser, M. Abstract LB-326: The role of HER3 in HER2-amplified cancers other than breast cancers. Cancer Res. 2020, 80, LB-326. [Google Scholar] [CrossRef]
  204. Crohn, B.B.; Rosenberg, H.N. The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am. J. Med. Sci. 1925, 170, 220–227. [Google Scholar] [CrossRef]
  205. Munkholm, P. Review article: The incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2003, 18 (Suppl. S2), 1–5. [Google Scholar] [CrossRef] [PubMed]
  206. Eaden, J.A.; Abrams, K.R.; Mayberry, J.F. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut 2001, 48, 526–535. [Google Scholar] [CrossRef] [PubMed]
  207. Lennard-Jones, J.E.; Morson, B.C.; Ritchie, J.K.; Williams, C.B. Cancer surveillance in ulcerative colitis. Experience over 15 years. Lancet 1983, 2, 149–152. [Google Scholar] [CrossRef] [PubMed]
  208. Eaden, J. Review article: Colorectal carcinoma and inflammatory bowel disease. Aliment. Pharmacol. Ther. 2004, 20 (Suppl. S4), 24–30. [Google Scholar] [CrossRef]
  209. Ekbom, A.; Helmick, C.; Zack, M.; Adami, H.O. Ulcerative colitis and colorectal cancer. A population-based study. New Engl. J. Med. 1990, 323, 1228–1233. [Google Scholar] [CrossRef] [PubMed]
  210. Karlén, P.; Löfberg, R.; Broström, O.; Leijonmarck, C.E.; Hellers, G.; Persson, P.G. Increased risk of cancer in ulcerative colitis: A population-based cohort study. Am. J. Gastroenterol. 1999, 94, 1047–1052. [Google Scholar] [CrossRef]
  211. Palli, D.; Trallori, G.; Bagnoli, S.; Saieva, C.; Tarantino, O.; Ceroti, M.; d’Albasio, G.; Pacini, F.; Amorosi, A.; Masala, G. Hodgkin’s disease risk is increased in patients with ulcerative colitis. Gastroenterology 2000, 119, 647–653. [Google Scholar] [CrossRef]
  212. Bernstein, C.N.; Blanchard, J.F.; Kliewer, E.; Wajda, A. Cancer risk in patients with inflammatory bowel disease: A population-based study. Cancer 2001, 91, 854–862. [Google Scholar] [CrossRef] [PubMed]
  213. Winther, K.V.; Jess, T.; Langholz, E.; Munkholm, P.; Binder, V. Long-term risk of cancer in ulcerative colitis: A population-based cohort study from Copenhagen County. Clin. Gastroenterol. Hepatol. 2004, 2, 1088–1095. [Google Scholar] [CrossRef] [PubMed]
  214. Jess, T.; Loftus, E.V., Jr.; Velayos, F.S.; Harmsen, W.S.; Zinsmeister, A.R.; Smyrk, T.C.; Schleck, C.D.; Tremaine, W.J.; Melton, L.J., 3rd; Munkholm, P.; et al. Risk of intestinal cancer in inflammatory bowel disease: A population-based study from olmsted county, Minnesota. Gastroenterology 2006, 130, 1039–1046. [Google Scholar] [CrossRef] [PubMed]
  215. Lakatos, L.; Mester, G.; Erdelyi, Z.; David, G.; Pandur, T.; Balogh, M.; Fischer, S.; Vargha, P.; Lakatos, P.L. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: Results of a population-based study. Inflamm. Bowel Dis. 2006, 12, 205–211. [Google Scholar] [CrossRef] [PubMed]
  216. De Campos Silva, E.F.; Baima, J.P.; de Barros, J.R.; Tanni, S.E.; Schreck, T.; Saad-Hossne, R.; Sassaki, L.Y. Risk factors for ulcerative colitis-associated colorectal cancer: A retrospective cohort study. Medicine 2020, 99, e21686. [Google Scholar] [CrossRef] [PubMed]
  217. Li, J.; Ma, X.; Chakravarti, D.; Shalapour, S.; DePinho, R.A. Genetic and biological hallmarks of colorectal cancer. Genes Dev. 2021, 35, 787–820. [Google Scholar] [CrossRef]
  218. Li, W.; Zhao, T.; Wu, D.; Li, J.; Wang, M.; Sun, Y.; Hou, S. Colorectal Cancer in Ulcerative Colitis: Mechanisms, Surveillance and Chemoprevention. Curr. Oncol. 2022, 29, 6091–6114. [Google Scholar] [CrossRef]
Biomolecules 14 00633 g001
Figure 1. Anatomic distribution of UC. (a) Healthy colon, and (b,c) normal anatomy of the healthy colon. Different degrees of UC: (d) proctitis, (e) proctosigmoiditis, (f) distal UC, (g) extensive UC, (h) pancolitis, and (i,j) normal anatomy of UC.
Figure 1. Anatomic distribution of UC. (a) Healthy colon, and (b,c) normal anatomy of the healthy colon. Different degrees of UC: (d) proctitis, (e) proctosigmoiditis, (f) distal UC, (g) extensive UC, (h) pancolitis, and (i,j) normal anatomy of UC.
Biomolecules 14 00633 g001
Biomolecules 14 00633 g002
Figure 2. The role of food-derived SCFAs in the regulation of intestinal homeostasis: SCFAs serve as an energy substrate. In addition, they regulates various intestinal factors, like upregulating the formation of MUC-2 to maintain a healthy gut, maintaining the integrity of the tight junction, regulating Treg cells and various factors like GPR-1, GPR-4, GPR-100, and GPR-109, and activating the anti-inflammatory pathway.
Figure 2. The role of food-derived SCFAs in the regulation of intestinal homeostasis: SCFAs serve as an energy substrate. In addition, they regulates various intestinal factors, like upregulating the formation of MUC-2 to maintain a healthy gut, maintaining the integrity of the tight junction, regulating Treg cells and various factors like GPR-1, GPR-4, GPR-100, and GPR-109, and activating the anti-inflammatory pathway.
Biomolecules 14 00633 g002
Biomolecules 14 00633 g003
Figure 3. On the left side, this diagram depicts the intricate relationship between environmental inputs, microorganisms, and the human host. On the right side, it shows how the gut microbiome can use undigested dietary poly- and oligosaccharides and further process them to SCFAs and other by-products (CO2, CH4, SH2, etc.); then, SCFAs can be absorbed by the human host, and other by-products can be excreted from the host’s body.
Figure 3. On the left side, this diagram depicts the intricate relationship between environmental inputs, microorganisms, and the human host. On the right side, it shows how the gut microbiome can use undigested dietary poly- and oligosaccharides and further process them to SCFAs and other by-products (CO2, CH4, SH2, etc.); then, SCFAs can be absorbed by the human host, and other by-products can be excreted from the host’s body.
Biomolecules 14 00633 g003
Biomolecules 14 00633 g004
Figure 4. This figure schematically represents a condition of colonic inflammation via excessive H2S produced by the gut microbiota. The Western diet can increase the number of H2S-producing bacteria in the gut, and the excessive H2S produced by the microbiota can be absorbed by the colonocytes. If this absorbed H2S exceeds the H2S disposal capacity of the sulfide oxidation unit (SOU) of the colonocytes, it increases the expression of pro-inflammatory interleukin-6 and iNOS and causes an inflammatory response.
Figure 4. This figure schematically represents a condition of colonic inflammation via excessive H2S produced by the gut microbiota. The Western diet can increase the number of H2S-producing bacteria in the gut, and the excessive H2S produced by the microbiota can be absorbed by the colonocytes. If this absorbed H2S exceeds the H2S disposal capacity of the sulfide oxidation unit (SOU) of the colonocytes, it increases the expression of pro-inflammatory interleukin-6 and iNOS and causes an inflammatory response.
Biomolecules 14 00633 g004
Biomolecules 14 00633 g005
Figure 5. The interactions between various factors and the development of UC. Exercise, healthy food, antioxidants, and increase the production of SCFAs to maintain a healthy gut, but lack of exercise, unhealthy food, stress, excessive drugs, and decrease the production of SCFAs, which consequently leads to leaky gut or the development of UC. Triggering the immune response in UC, the main molecules involved are GPR-109, macrophage, dendritic cells, T regulatory cells, IL-6, IL-9, IL-18, and TNF-γ.
Figure 5. The interactions between various factors and the development of UC. Exercise, healthy food, antioxidants, and increase the production of SCFAs to maintain a healthy gut, but lack of exercise, unhealthy food, stress, excessive drugs, and decrease the production of SCFAs, which consequently leads to leaky gut or the development of UC. Triggering the immune response in UC, the main molecules involved are GPR-109, macrophage, dendritic cells, T regulatory cells, IL-6, IL-9, IL-18, and TNF-γ.
Biomolecules 14 00633 g005
Biomolecules 14 00633 g006
Figure 6. This figure schematically represents how the Western-type diet and other contributing factors cause colonic inflammation by changing the gut microbiota composition. This change can modulate the production of microbiota-produced metabolites, which then cause epigenetic changes in the host genome, thereby inducing inflammatory responses in UC.
Figure 6. This figure schematically represents how the Western-type diet and other contributing factors cause colonic inflammation by changing the gut microbiota composition. This change can modulate the production of microbiota-produced metabolites, which then cause epigenetic changes in the host genome, thereby inducing inflammatory responses in UC.
Biomolecules 14 00633 g006
Table 1. Major types of cultivable bacteria found in the feces of an adult person [83].
Table 1. Major types of cultivable bacteria found in the feces of an adult person [83].
Type of BacteriaGenusApprox. Count gm/Feces
Gram-negative bacilliBacteroides1010
Fusobacterium109
Gram-positive bacilliEubacterium1010
Bifidobacterium1010
Lactobacillus104–8
Clostridium1010
Cocci Gram-negative and Gram-positiveRuminococcus1010
peptostreptococcus
anaerobic streptococcus
Facultative anaerobic EnterobacteriaceaeE. coli1010
Citrobacter
Enterobacter
Proteus
Klebsiella
Pathogen eg Shigella, Salmonella, Yersinia
Table 2. Follow-up of CRC cases in UC patients.
Table 2. Follow-up of CRC cases in UC patients.
Number of UC PatientsDeveloped CRC CasesFollow-Up Period
(Person-Years)		Annual Crude Incidence (%)Cumulative Incidence at 30 Years (%)Study LocationReference
2672361984–1997
(19,655)		0.16Not reportedManitoba, Canada[212]
37861940–2004 (5567)0.102Olmsted County, USA[214]
1160131962–1987 (22,290)0.062.1Copenhagen County, Denmark[213]
689101978–1992
(7877)		0.12Not reportedFlorence, Italy[211]
723131974–2004
(8564)		0.157.5Veszprem, Hungary[215]
267213 rectum1984–1997
(19,655)		0.06Not reportedManitoba, Canada[212]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Majumder, A.; Bano, S. How the Western Diet Thwarts the Epigenetic Efforts of Gut Microbes in Ulcerative Colitis and Its Association with Colorectal Cancer. Biomolecules 2024, 14, 633. https://doi.org/10.3390/biom14060633

AMA Style

Majumder A, Bano S. How the Western Diet Thwarts the Epigenetic Efforts of Gut Microbes in Ulcerative Colitis and Its Association with Colorectal Cancer. Biomolecules. 2024; 14(6):633. https://doi.org/10.3390/biom14060633

Chicago/Turabian Style

Majumder, Avisek, and Shabana Bano. 2024. "How the Western Diet Thwarts the Epigenetic Efforts of Gut Microbes in Ulcerative Colitis and Its Association with Colorectal Cancer" Biomolecules 14, no. 6: 633. https://doi.org/10.3390/biom14060633

APA Style

Majumder, A., & Bano, S. (2024). How the Western Diet Thwarts the Epigenetic Efforts of Gut Microbes in Ulcerative Colitis and Its Association with Colorectal Cancer. Biomolecules, 14(6), 633. https://doi.org/10.3390/biom14060633

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop